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Abstract
B cells are implicated in the pathogenesis of type 1 diabetes (T1D), a serious
autoimmune disease. It has been found that in nonobese diabetic (NOD) mice,
a well described animal model of T1D, there is an enlarged thymic B cell pop-
ulation, not seen in non diabetic B6 mice, and such B cells may contribute to
T1D development. The mechanisms by which B cells are populating the NOD
thymus are unknown and delineating the mechanisms would offer new insights
into abnormalities of the NOD thymus that may contribute to T1D.
This project investigated potential intrathymic B cell development of B cells
in NOD mice, compared to B6 mice. Molecular biological approaches determ-
ined that transcripts of essential B cell development transcription factors were
present in the NOD thymus. Flow cytometric studies established the presence
of thymic pro and pre B cells, as well as thymic CD19+ cells expressing RAG
enzymes, indicating active rearrangement of the B cell receptor that is crucial
for pro to pre B cell progression. Interestingly, comparative studies using B
cell sufficient and deficient NOD mice revealed that mature B cells appear to
play an important role in the enhancement of the thymic pro B cell population
frequency. In contrast to pro B cells, the frequency of the earliest B cell progen-
itors in the NOD thymus was independent of mature B cells. B cell committed
progenitors were decreased in the NOD thymus compared to the B6 thymus,
suggesting that there may be an alternative B cell development pathway in the
thymus compared to the bone marrow.
The data presented here provides a novel insight into the NOD thymus at the
level of thymic B cells. Future studies to establish the definitive mechanisms for
thymic B cell development, and their role in the T1D process will be informat-
ive.
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Introduction
1.1. Diabetes - Facts and Figures
Diabetes mellitus is a condition affecting the body’s ability to control blood
sugar levels. According to statistics provided by Diabetes UK, diabetes affects
approximately 3.9 million people in the UK, with many more sufferers, as yet,
undiagnosed. The incidence of diabetes is rising rapidly, with the prevalence of
diabetes in the UK now being more than double that of 1996 [1].
Diabetes results from either lack of, or resistance to, the hormone insulin. The
pathogenesis of the disease depends on the type of diabetes in question. There
are a few types of diabetes including gestational diabetes, seen in some preg-
nancies, type 1 diabetes, and type 2 diabetes [1]. Type 1 diabetes (T1D) is an
autoimmune condition where the body’s own immune system destroys insulin
producing cells, resulting in a lack of insulin. Type 2 diabetes (T2D), on the
other hand, is when the body becomes resistant to the action of insulin and
insulin production is impaired. Both type 1 and type 2 diabetes result in a
decreased ability to regulate blood glucose levels [2].
Insulin is produced in the pancreas by β cells in the Islets of Langerhans. It is
a vitally important hormone involved with the maintenance of normal blood
glucose levels, in particular stopping dangerous rises in blood glucose levels.
Insulin’s main actions are to stop the production of extra glucose when blood
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glucose is already sufficiently high. It does this by keeping the brakes on mech-
anisms of glucose production such as glycogenolysis (breakdown of glycogen
stores), lipolysis (breakdown of fats) and proteolysis (breakdown of protein).
It also prevents the production of glucagon, the hormone which acts to raise
glucose levels [3].
The dysregulation of blood glucose levels seen in diabetes is what causes the
many complications seen in the disease. It is, therefore, crucial for the patient
to carefully monitor and control blood glucose by diet and/or medication, de-
pending on type and severity of the diabetes. Alongisde the characteristic dia-
betes symptoms of excessive thrist, drinking and urination, there are serious
side effects both in the short and longer term. In the short term, extremes of
blood glucose, either too high or too low, can lead to hyper- or hypoglycaemia
which require fast treatment in order to prevent potentially lethal conditions
such as diabetic ketoacidosis in T1D, or hyperosmolar hyperglcaemic state in
T2D [1, 4]. In the longer term, prolonged mild hyperglycaemia caused by dia-
betes can cause micro- and macrovascular complications leading to blindness,
neuropathy, kidney failure and a significantly increased risk of cardiovascular
disease [4]. It is therefore vitally important for research into diabetes to con-
tinue, with the aim of finding a cure.
1.1.1. Type 1 Diabetes
This project is concerned only with type 1 diabetes (T1D). T1D is a serious
autoimmune condition whereby the host’s own immune system destroys β cells
in the pancreatic Islets of Langerhans [5]. Destruction of β cells results in a lack
of insulin and forces the patient to rely on self monitoring of blood glucose
through regular finger prick blood testing and subsequent insulin administra-
tion. Until recently it was thought that T1D led to a total obliteration of β cells,
however, it is now thought that very small numbers of β cells remain and are
able to secrete insulin [6, 7]. Type 1 diabetes affects approximately 10% of all
diabetes sufferers [1].
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1.2. The Immune system
1.2.1. Role
The immune system evolved to protect animals from a variety of pathology-
inducing agents such as bacteria, protozoa, viruses and fungi. The immune
system is designed to recognise invading pathogens and eliminate them be-
fore they can cause harm to the host. The immune system consists of two
interconnecting arms known as the innate immune system and the adaptive
immune system. The innate system is the more primitive, non specific system
whereas the adaptive immune system is highly specific and capable of recog-
nising unique components on pathogens. The cells and processes involved in
each arm of the immune system are different but are interconnected through
cell-cell interactions and cytokine and chemokine secretion so that pathogens
can be targetted in the most effective way [8–10].
1.2.2. The Innate Immune System
The innate immune system is characterised by being non specific, fast acting
and incapable of forming immunological memory. The aim of the system is to
prevent entry of pathogens and recognise, engulf and destroy pathogens which
have managed to invade. Following this, pathogenic antigens are presented to
cells of the adaptive immune system and inflammatory cytokines are produced
to signal to other immune cells and boost the immune response [9].
The innate immune system has numerous ways of preventing pathogen entry,
such as the skin and epithelial tight junctions providing physical barriers and
enzymes, antimicrobial peptides and mucus to catch and kill pathogens trying
to enter [9, 10].
However, should microorganisms gain entry to the body, there are innate im-
mune cells which can take over. These include phagocytes (macrophages, dend-
ritic cells (DCs) and neutrophils) and natural killer (NK) cells. To recognise
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invading pathogens, cells of the innate immune system have a number of dif-
ferent receptors, both membrane bound and free in the cytosol. These pattern
recognition receptors (PRRs), such as Toll-like receptors (TLRs), C-type Lectins,
NACHT-leucine rich repeat receptors (NLRs) and Rig-like receptors (RLRs) are
capable of recognising a variety of patterns expressed only by microbes, known
as pathogen-associated molecular patterns (PAMPs) [11, 12]. Binding through
receptors such as these transmits signals into the cells resulting in subsequent
release of inflammatory cytokines, upregulation of major histocompatibility
complex (MHC) Class II, upregulation of costimulatory molecules (vital for
antigen presentation, see below), and upregulation of killing mechanisms fol-
lowing phagocytosis of pathogens. The ability to recognise these PAMPs gives
the innate immune system to ability to distinguish self from non-self [11].
However, the immune system is not only there to protect from invading or-
ganisms. Damaged host cells also require removal by the immune system to
prevent inflammation and potential autoreactive responses. In order to do this,
it is thought that the innate immune system is also able to recognise damage-
associated molecular patterns (DAMPs) on damaged host cells which can also
bind to TLRs and ellicit an immune response [13, 14]
1.2.3. The Adaptive Immune System
The adaptive immune system is different from the innate immune system in
that it is slower acting, highly specific and has the ability to form immunolo-
gical memory [10]. The adaptive immune system is concerned with tailoring
the immune response to a specific pathogen.
The adaptive immune system is composed of T and B lymphocytes, also known
as T and B cells. These cells express receptors which are specific to a given
antigen. Each T and B cell has a different antigen specificity, therefore, the
adaptive immune system can recognise a huge number of antigens via B and T
cell receptors [9].
However, B and T cells require activation before they can function. In order to
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activate these cells, they must first encounter their cognate antigen (i.e, the an-
tigen for which their receptor is specific) [10]. B cells are capable of recognising
whole protein, whereas T cells require their antigen to be degraded into peptide
fragments and presented to them by antigen presenting cells (APCs) [9]. Once
activated, B and T cells are able to carry out their functions.
The functions of the adaptive immune cells vary. T cells have many different
subsets with differing functions depending on the subset. Some are concerned
with orchestrating the overall immune response (T helper cells) while others are
designed to kill their target cells directly (killer T cells). These will be discussed
in more detail in Section 1.3.3. B cells are capable of antigen presentation but
their main function is antibody production. Antibodies are the secreted form
of the B cell receptor and are designed to help with removal of the pathogen
by phagocytosis or complement (a process consisting of a variety of different
proteins aimed at the destruction of pathogens) and to help neutralise harmful
toxins produced by microorganisms [15].
1.2.4. Receptor Rearrangement
As mentioned above, T and B cells have receptors on their surface that are
specific to their cognate antigens. T cells have a T cell receptor (TcR) and B
cells have a B cell receptor (BcR). Each B and T cell has a unique receptor
which results in a massive repertoire of receptors, each capable of responding
to a different antigen. Due to both types of receptor requiring a huge potential
for diversity, the mechanisms which introduce this diversity during receptor
development are largely the same for both receptor types.
There are two types of TcR, each consisting of two chains. The main one is an
αβ receptor which is most common, and the second is a γδ receptor [9]. In the
BcR, there are also two chains, known as the heavy and light chain [16]. The
heavy chain is equivalent to either the β or δ chains, while the light chain is
equivalent to the α or γ chains. The receptor chains consist of a variable and
constant region. The variable region is the part which is capable of recognising
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antigen [16].
The variable region is made up of V (variable), D (diversity, found only in heavy,
β and δ chains) and J (joining) gene segments. Genomically encoded are mul-
tiple copies of different V, D and J genes and during rearrangement, one of each
of these genes is selected at random and joined to produce different receptors
[17]. This process is mediated by enzymes known as RAG (recombination activ-
ating genes) recombinases [10]. These enzymes recognise recombination signal
sequences (RSS) found next to the coding regions of each V, D and J gene and
bring the ends of the chosen genes near to each other to be joined [17, 18]. To
join the segments, RAG proteins cleave at either end of the genes and leave hair-
pin loops of DNA. From here a nuclease nicks the loops leaving short sequences
at the end of each gene to be joined. This allows the segments to join via non
homologous end joining [19]. Further diversity is then added via the use of an
enzyme called terminal deoxynucleotidyltransferase (TdT) which adds random
base pairs between each segment [20]. Combined, all these mechanisms allow
for the formation of approximately 1013-14 possible receptors [8, 20].
1.3. T cells
1.3.1. Development
T cells develop in the thymus. Since the thymus does not contain self-renewing
thymocytes, the process of T cell development relies on the constant seeding
of the thymus by progenitors from the bone marrow [21, 22]. However, the cell
that is responsible for this seeding and acts as a T cell progenitor is not known.
There are many candidates and these have been identified by looking at the
surface markers that are required for a cell to be able to settle in the thymus
and develop into a T cell.
Haematopoietic stem cells (HSCs) are the progenitors from which all blood cells
derive. These cells are found in the bone marrow and, via the production of
various progenitors, can produce megakaryocytes, erythrocytes, lymphocytes,
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granulocytes, macrophages and NK cells. HSCs are characterised by their lin-
eage (lin)-, stem cells antigen-1 (Sca-1)high, stem cell growth factor receptor (c-
kit)high phenotype (so-called LSK cells). HSCs also lack surface fms-like tyrosine
kinase 3 (Flt3) expression [23].
Following the HSC stage, multipotent progenitors (MPPs) form which have
the capability of producing all types of blood cell, but lack the self-renewing
ability of HSCs. These cells are LSK but also express Flt3low [23]. Interestingly,
MPPs can express genes of multiple lineages [24] suggesting that this expres-
sion is due to priming for lineage committment, rather than commitment itself.
It is thought that by expressing these genes, it maintains them in an accessible
chromatin state, ready for commitment [23]. Evidence for this has been seen
through changes in chromatin staus of lineage restricted genes during blood
cell development [25].
Following MPP development, magakaryocytic and erythrocytic potential is much
reduced and the so-called lymphoid primed multipotent progenitor (LMPP)
arises. These cells are capable only of lymphocyte, macrophage, granulocyte
and NK cell production [26]. LMPPs are characterised by being LSK but also
Flt3high.
Next, the interleukin-7 receptor-α (Il-7Rα) upregulates and Sca-1 and c-kit down-
regulate to form common lymphoid progenitors (CLP). These cells are capable
only of B and T lymphocyte development and NK cell development [27] and
have a Sca-1low c-kitlow Flt3+ Il-7Rα+ phenotype. Flt3 is the receptor for Flt3 lig-
and (Flt3L) which is found in the bone marrow and acts as a growth promoter
for CLPs. Flt3L also works synergistically with IL-7 to promote lymphocyte
proliferation [28]. CLPs will be discussed further in Section 1.4.1.
There are many candidate thymic settling progenitors (TSPs). It appears that
TSPs must express Flt3, which rules out HSCs as thymic seeding progenitors,
[21], and also chemokine receptor (CCR) 9 or CCR7 or both [29]. CCR9 and
CCR7 are chemokine receptors which are important for allowing thymic set-
tling. While the expression of only one type of chemokine receptor is sufficient,
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it is more efficient if both are expressed. These requirements for settling suggest
that likely candidates for TSPs are CCR7+CCR9+ LMPPs and CLPs[21].
Following the thymic settling of precursors, T cells progress into the four step
double negative phase (DN1-4), where they express neither cluster of differenti-
ation (CD) molecules CD4 or CD8. During their time in this phase, particularly
in DN3, the TcR begins to rearrange by the mechanisms outlined in Section 1.2.4
[30]. Following rearrangement, T cells are able to continue to the double posit-
ive (DP) stage where thy express both CD4 and CD8 molecules [31].
In the DP stage, T cells undergo their first round of education, known as pos-
itive selection. This is the process whereby all developing T cells are exposed
to thymic cortical epithelial cells (cTECs) expressing MHC class I and MHC
Class II. If the T cell doesn’t recognise either MHC Class, or binds with a very
high affinity, they receive a death signal and are deleted by apoptosis. However,
for those T cells that bind to one of the MHC Classes with the correct affinity,
they receive a survival signal and continue with their development. This pro-
cess is to eliminate all those T cells that wouldn’t be able to recognise self MHC
presenting peptide and all those which may react dangerously to it [30, 32].
Assuming a T cell is positively selected, the type of T cell it will become (CD4+
or CD8+) depends on which MHC Class it recognised. For example, if a T cell
recognised MHC Class II, it develops into a CD4 single positive (CD4+) T cell
or if it recognised MHC Class I, it becomes a CD8 single positive (CD8+) T cell.
Following positive selection, T cells then move from the thymic cortex to the
medullar where they are exposed to medullary thymic epithelial cells (mTECs)
which mediate the process of negative selection [30]. This process is an import-
ant step in preventing autoreactivity as it is here that developing T cells are
presented with self antigens. mTECs express autoimmune regulator (AIRE), an
enzyme which is capable of producing many self antigens so that mTECs can
present their peptides alongside MHC molecules to T cells to test the reactivity
of the TcR to the host antigen [33]. The affinity with which T cells can recog-
nise these self-antigens via their TcR is important for determining whether or
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not a T cell is allowed to continue developing [34]. Cells which bind strongly
to the self antigens are given a death signal as these T cells, upon comple-
tion of their development and migration out of the thymus into the periphery,
could potentially recognise host antigen and attack the tissue. This is known as
autoimmunity.
The aim of negative selection in the thymus is to only allow the release T cells
that will not react to host antigens. Negative selection is, therefore, the first
step in preventing autoimmunity by tolerising the T cell repertoire through
removal of self-reative T cell clones [35] (T cell tolerance is discussed further in
Section 1.3.5.)
1.3.2. Genes and Transcription factors driving T cell development
T cell development relies on expression of specific genes and transcription
factors to drive development in the lineage. The first stage of T cell develop-
ment is the development of early thymic progenitors (ETPs) from TSPs arriving
in the thymus. There are a number of transcription factors that help with this
process and, indeed, deficiency in any of these transcription factors can lead
to a decrease in the ETP population without affecting their progenitors. These
transcription factors include Notch1, T-cell factor 1 (TCF-1) and GATA-binding
protein 3 (Gata3) [36–39].
Notch is a very important transcription factor for T cell commitment. The pro-
genitors seeding the thymus arrive from the thymus and it is seems that some
of these progenitors may retain B cell potential [40]. Notch expression is capable
of suppressing B cell lineage commitment by suppression of B cell development
transcription factors, such as paired box 5 (Pax5) (See Section 1.4.2) so that T
cell development is promoted. It has been found that inactivation of Notch1
in bone marrow progenitors results in a block in T cell development and the
formation of ectopic B cells in the thymus, suggesting it’s expression is crucial
for T cell development. Further evidence is shown by constitutive expression of
Notch1 in the bone marrow causing T cells to develop abnormally in the bone
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marrow [41]. These actions show that it is important for transcription factor
balance to be maintained in order to support normal lymphocyte development
in the correct place.
E2A is a protein encoding two transcription factors, E12 and E46. E2A proteins
are also important in T cell development and their actions appears both up-
stream of Notch1 by affecting LMPPs [42], and downstream, helping to drive T
cell transition from DN1 to DN2 [37]. As well as this, it appears to regulate the
expression of Notch1 itself [42].
There are also other transcription factors involved in T cell development, such
as RUNT-related transcription factor (Runx) and Bcl11b [37, 43]. Runx is import-
ant for progression from ETP to DN2 and DN2 to DN3, while Runx appears to
be essential for absolute T lineage commitment in the late DN2 stage [37, 43].
Prior to absolute T cell commitment, DN2 cells retain DN, NK and macrophage
potential [37].
1.3.3. Role
There are different types of T cells and they all have different functions as
outlined below:
– CD4+ Helper T lymphocytes - CD4+ Helper T cells (CD4+ T cells) are cells
which are able to help other immune cells carry out their own functions.
Helper T cells express CD4 which allows them to respond to peptide anti-
gens held in MHC Class II on the surface of APCs. Activated CD4+ T cells
are able to help with CD8+ cytotoxic T cell activation and B cell antibody
production.
– CD8+ Cytotoxic T lymphocytes - CD8+ cytotoxic T cells (CTL) are produced
through activation of CD8+ T cells. Once activated, CTLs are capable of
killing off their target cells in a highly specific manner.
– Regulatory T cell - There are many types of regulatory T cells (Tregs) which
all act to suppress harmful immune responses in the periphery, either by
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producing cytokines which inhibit harmful immune responses (such as IL-
10), killing immune cells to prevent their harmful action, disruption of im-
mune cell metabolism, or modulation of APC function/maturation [44].
1.3.4. T cell Activation
Antigen presentation is the process by which the innate immune system can
signal to the adaptive immune system that an immune response is required.
Professional APCs (macrophages, DCs and B cells (see Section 1.4) scavenge
pathogens when they invade and internalise them. From here they breakdown
the pathogen, then express it’s antigen either on MHC Class II (to activate CD4+
T cells), or MHC Class I (to activate CD8+ T cells).
For T cells to become activated, they must be presented with their cognate
antigen in the peptide/MHC complex on an APC. T cell activation requires
three signals as follows [45, 46]:
1. Signal one - TcR must recognise the peptide/MHC complex on the APC
2. Signal two - Costimulatory molecules CD86 or CD80 on the APC must
bind CD28 on the T cell. Costimulatory molecules are only expressed by
APCs in inflammatory conditions
3. Signal three - Cytokines released by the APC influence the type of effector
cell that the T cell will become. For example, CD4+ helper T cells can
become Th1, Th2 or Th17 effector cells, depending on signals from the
APC and the type of immune response required [46]
CD8+ T cells are activated differently to CD4+ T cells, in that they will only
respond to MHC Class I. This process requires a process known as cross-
presentation by the APC. Normally, exogneous antigens (i.e. those from out-
side a cell) are processed and expressed on MHC Class II, whereas endogenous
antigens (i.e. antigens from inside the cell, either damaged components or intra-
cellular pathogens) are processed and displayed on MHC Class I. MHC Class
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I is expressed on every nucleated cell and therefore provides a mechanism by
which cells can signal that they are virally infected or cancerous.
However, for CD8+ to become activated, they need to be presented with their
antigen and costimulatory molecules which are only present on APCs. This
requires a process known as cross presentation by the APC, whereby an exo-
genous antigen can be processed and subsequently presented on MHC Class I
to activate CD8+ T cells [47].
Following activation, CD8+ T cells can become CTLs and kill off any cell ex-
pressing it’s cognate antigen on MHC Class I. CTLs are therefore important
cells for the clearance of viruses and can help with cancer prevention. CTLs kill
off their target cells in a highly specific manner using perforins and granzymes
[9].
1.3.5. Tolerance
Due to T cells having huge receptor diversity, there is potential for some TcR
clones to be reactive to host antigens. Therefore, there are mechanisms in place
to prevent the release or action of autoreactive T cells.
T cells begin their education and tolerisation process in the thymus, however,
purging of autoreactive T cells in the thymus by negative selection, is not abso-
lute. For example, not all self antigens can be expressed in the thymus therefore
developing T cells cannot be tolerised to all self tissues. Another problem is
that in negative selection, the avidity of binding to MHC/peptide complexes
determines whether or not T cells are allowed to develop. The risk of mak-
ing this process too stringent is that the receptor repertoire may be cut down
too much and, therefore, the ability to fight pathogens may be reduced [35].
With these limitations in mind, it is necessary for there to be further regulatory
mechanisms in place in the periphery.
As such, peripheral tolerance mechanisms exist to regulate the autoreactive
cells that have escaped central tolerance. These mechanisms include:
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– Induction of anergy - T cells engage with their antigen on an APC but in
the absence of costimulation. This stops the T cell becoming activated and
renders it unresponsive to its antigen [48]
– Deletion [48]
– Suppression by regulatory T cells [48]
Autoimmune disease is believed to be linked to failures in tolerance mechan-
isms so that the production of autoreactive lymphocytes is not controlled prop-
erly.
1.4. B cells
B cells have two physiological roles, antigen presentation and antibody pro-
duction. Whilst B cells are APCs, their main function is antibody production.
Antibodies are an important part of the adaptive immune response which help
with the neutralisation of toxins, phagocytosis of pathogens and destruction of
bacteria and viruses. Early B cell development occurs in the bone marrow then
immature B cells move to the spleen to mature.
B cells also play an important role in the pathogenesis of T1D. This will be
discussed in more detail in Section 1.6
1.4.1. Development - Stem cells to maturity
B cell development is summarised in Figure 1.1.
B cell commitment
The bone marrow is the normal site of B cell development. As mention in Sec-
tion 1.3.1, all blood cells, including lymphocytes are formed from Lin- Scahigh
c-kithigh HSCs found in the bone marrow (Figure 1.1, dark blue cell). HSCs then
form Lin- Scahigh c-kithigh Flt3low MPPs which can form all types of blood cells
but lack the self-renewal of HSCs (Figure 1.1, bright blue cell) [23]. From here,
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Lin- Scahigh c-kithigh Flt3high LMPPs form which are capable only of lympho-
cyte, macrophage, granulocyte and NK cell production (Figure 1.1, pale blue
cell) [26]. CLPs are characterised by Sca-1low c-kitlow Flt3+ Il-7Rα+ expression
and are capable only of B and T cell and NK cell development (Figure 1.1,
orange cell) [27].
However, further research into CLPs has revealed significant heterogenity within
the population. Many different groups have used different methods, markers
and reporter systems in order to try and identify a subpopulation of CLPs
which is restricted to the B cell lineage. Some of these are outlined below:
– Mansson et al. [49] showed that, based on the expression of λ5 (a B cell
gene) and Rag1, the CLP compartment could be subdivided into cells that
are able to develop into T, B and NK cells, cells that are able to develop
into T and B cells, and those that are B cell restricted. Using λ5 reporter
mice crossed with Rag1 reporter mice, it was found that CLPs could be
divided into three populations. λ5-Rag1low cells which developed into T, B
and NK cells, L5-Rag1high which developed into T and B cells with reduced
NK cell potential, and λ5+Rag1high cells which were B cell lineage restricted.
They also found that the λ5highRag1high cells had increased expression of
the surface marker Ly6D.
– Inlay et al. [50] on the other hand, used Ly6D expression as a marker for
determining B cell lineage commitment. For their investigations they split
CLPs into Ly6D+ and Ly6D- fractions and then looked at their ability to
produce T, B and NK cells. Interestingly, Ly6D- CLPs were able to produce
all three types of progeny and were, therefore, termed all-lymphoid pro-
genitors, ALPs. On the other hand, Ly6D+ CLPs were almost totally B cell
committed and, therefore, termed B cell-biased lymphoid progenitors, BLPs.
– Lastly, Zhang et al. [51] focused on the expression of Ly6D and Rag1 as
markers to follow B cell commitment and differentiation. The CLP compart-
ment was split based on Flt3 expression, Rag1 expression and Ly6D expres-
sion. It was found that those cells expressing Ly6D and Rag1 were the most
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potent at producing B cells. Most of these cells also expressed Flt3. These
B cell producing cells also had the highest levels of B cell gene transcripts
(for example, Rag1, EBF, Pax5, see Section 1.4.2) indicating B cell lineage
progression.
It therefore appears that within the CLP stage, there are subpopulations of cells
which have leanings towards different lineages. It may be that the appearance of
these different subpopulations is linked to the developmental stage of the CLP.
For example, the more committed progenitors might be more developed CLPs
compared to less committed progenitors. It appears that Rag1 and Ly6D are
very important in determining B cell restricted progenitors and that it is reason-
able to hypothesise that a committed B cell progenitor, B-cell biased progenitor
(BLP), could have the phenotype of Sca-1low c-kitlow Flt3+ IL-7Rα+ Ly6D+ with
evidence of previous Rag1 expression and robust levels of B cell development
gene transcripts (Figure 1.1, red cell labelled ‘BLP’).
Following the development of B cell comitted progenitors, these cells then go on
to express B220 (expressed on B cells and some plasmacytoid DCs), followed by
CD19. Originally it was thought that B cells were only committed to the B cell
lineage once B220 and CD19 were being expressed, however, there is now much
evidence to suggest that this commitment step occurs prior to their expression
[52].
Committed B cell development
Following commitment to the B cell lineage and the expression of CD19, B cells
then progress through the following stages (Figure 1.1, light through to dark
purple cells) [53]:
– Pro B cell - characterised as CD19+CD43+IgM-
– Pre B cell - characterised as CD19+CD43-IgM-
– Immature B cell - characterised as CD19+CD43-IgM+
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Figure 1.1: Schematic overview of B cell development in the bone marrow. Development of B
cells from HSCs through the various progenitors is shown here. The surface markers
associated with each developmental stage is shown on the left. On the right hand
side, the haematopoietic cells which arise from each progenitor are listed. The point
of IgM heavy chain rearrangement at the pro to pre B cell transition is shown in
green. (Imm B = Immature B cell).
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For progression from the pro B cell stage to the pre B cell stage, pro B cells must
begin the rearrangement of their IgM heavy chain (see below).
Following the production of immature B cells in the bone marrow, they then
leave the bone marrow and migrate to the spleen to mature. This is facilitated
by the increase in IgM expression during development which allows immature
B cells to become transitional B cells and migrate towards the centre of the bone
marrow. From here they are carried by the central sinus, then venous circulation
to the spleen [54].
B cell receptor development
As mentioned in Section 1.2.4, the BcR is the B cell’s way of identifying patho-
gens in a very specific manner and there are many mechanisms in place in
order to introduce high levels of diversity into the BcR repertoire.
The structure of a BcR consists of 2 heavy chains, which have a constant region
and a variable region. Alongside these are two light chains, which also consist
of a constant and variable region. Each light chain sits alongside the heavy chain
with the two variable regions next to each other. Between them, the variable
regions make up the antigen binding site [16].
In order to progress from the pro B to the pre B cell stage, the rearrangement
of the IgM heavy chain must begin (Figure 1.1, green text/arrow). Once this
has happened, it can be coupled to a surrogate light chain to form the pre-BcR
which has the role of initiating light chain rearrangement so that a full IgM
molecule can be produced [55]. The transition from pro B to pre B cells is also
the first point of screening for autoreactivity [16].
The BcR may either be membrane bound or secreted in the form of antibody.
Antibodies are produced by B cells that have differentiated into plasma cells
and are secreted into the blood stream to help with pathogen toxin neutralisa-
tion, phagocytosis and complement activation [15]. The constant region gives
the antibody its class, for example, IgM, IgD, IgE, IgA, IgG [16]. Each antibody
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class has a different function, for example, IgE is important in allergic reactions
and IgA is important for mucosal immunity.
1.4.2. Genes and Transcription Factors driving B cell development
The process of B cell development is reliant on the expression of particular
genes and transcription factors.
Transcription factor PU.1 (PU.1) is an important transcription factor which re-
quires repression in order to allow B cell development [56]. Without this repres-
sion, myeloid cell development is encouraged, therefore PU.1 is said to act in
a dose dependent manner. PU.1 is regulated by growth factor independent 1
transcription repressor (Gfi-1), which is controlled by Ikaros family zinc finger
protein 1 (Ikaros), a transcription factor known for it’s importance in allowing
B cell development [57, 58].
Lowered expression of PU.1 upregulates the expression of IL-7Rα, early B-cell
factor 1 (EBF) and Pax5 which are all important factors for B cell development
[59]. PU.1 acts on progenitors in order to aid production of CLPs [59].
Downstream from CLPs, factors such as E2A, EBF and Pax5 all become import-
ant in the commitment to, and progression within the B cell lineage [52]. E2A
encodes two transcription factors, E12 and E46, both of which are important
for B cell development [60], shown by the developmental block prior to the
pro B cell stage in the absence of E2A [61]. E2A is also a requirement for the
expression of EBF, which in turn activates genes crucial to BcR development,
such as VPreB (a surrogate light chain) [23]. Alongside gene activation, Ebf-1
also activates the transcription factor forkhead box protein O1 (FOXO1) which
is important for continued B cell development and Rag expression [62].
Pax5 is also an important transcription factor. Originally, it was believed to
be the factor that coincided with B cell commitment, however, there is now
evidence to suggest that B cell commitment occurs prior to Pax5 expression
[23]. It is now thought that Pax5 is important for progression in the B cell
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lineage, rather than commitment. Mature B cells made deficient in Pax5 have
been shown to be able to dedifferentiate from the B cell lineage, suggesting that
Pax5 is important in maintaining lineage restriction [63]. Pax5 is also important
for the repression of the T cell lineage through repression of Notch1 [64].
Although not a transcription factor, the cytokine CXCL12 is important during B
cell development in the bone marrow as it holds developing B cells in the bone
marrow niche. It is produced by stromal cells and haematopoietic progenitor
cells attach themselves to the processes extending from the CXCL12-producing
cells and developing B cells attach themselves to the progenitor bodies [65].
1.4.3. Tolerance
Due to the huge receptor diversity produced by V(D)J recombination, it is in-
evitable that some combinations will produce receptors responsive to self anti-
gens. Therefore, there are many mechanisms in place to help avoid the release
and action of these potentially autoreactive clones.
Some methods of dealing with potentially autoreactive B cells are as follows:
– Deletion - B cells are exposed to self antigens in the bone marrow. If B cells
are able to respond to self antigen, the maturation process of the B cell is
halted and the B cell dies [66]
– Receptor editing - B cells can have another chance at rearranging their light
chain in order to try and produce a different, non autoreactive recptor [67,
68]
– Receptor dilution - in rearranging an alternative light chain, the B cell ex-
presses both the autoreactive and the non autoreactive receptors which
downregulates the concentration of autoreactive receptor [67, 68]
– Induction of anergy - B cells become unreactive to their antigen [67]
These mechanisms are employed both in the bone marrow during development
and following release into the periphery. However, once the B cells have left the
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bone marrow, receptor editing is not an option.
1.5. The Nonobese Diabetic Mouse
The nonobese (NOD) mouse is a well described animal model of T1D, first
discovered by Makino et al. [69] in 1980, where insulin producing β cells are
believed to be destroyed by autoreactive T cells, predominantly CD8+ CTL [70].
It is a model that is genetically predisposed to develop T1D by a well char-
acterised pathogenesis, over a defined time course as outlined below and in
Figure 1.2.
1. Sensitisation - Initial priming of T cells to islet antigen which takes place
in the pancreatic lymph node (PLN)
2. Infiltration and insulitis - cells of the immune system move to the pancre-
atic islets and infiltrate the tissue. This is known as insulitis. For a while,
the autoreactive cells’ aggressive functions are suppressed by regulatory
mechanisms and no damage occurs
3. β cell destruction - regulatory mechanisms become impaired and activ-
Figure 1.2: Schematic representation of the T1D process in NOD mice. At 3-4 weeks of age,
autoreactive T cells become primed to islet antigen. Following this, immune cells
move to the pancreatic islets, a process termed insulitis. Initially, regulatory mech-
anisms remain intact and β cells are preserved. However, regulatory mechanisms
soon break down and by 12 weeks of age, CTL-mediated β cell destruction is well
established and T1D is detectable in the NOD mouse colony.
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ated CD8+ T cells become cytotoxic T cells (CTLs) which begin to target
and destroy β cells. β cells are believed to die by apoptosis [2].
It is believed that the NOD mouse is a relevant model for T1D research as the
human disease is thought to follow a similar pathogenesis. It has been seen in
donated human diabetic tissues that there is infiltration of islets, albeit reduced
compared to that seen in the NOD mouse [7], and it is thought that β cell
destruction is mediated by CTLs, similar to that seen in the NOD mouse [71].
Each of the stages of T1D development will be discussed further in the relevant
sections below.
1.5.1. Initiation of T1D
It is thought that both the innate and adaptive immune system have roles to
play in the initiation of T1D, through PRR binding, release of inflammatory
cytokines and activation of T and B cells [72].
Autoantigens believed to be important in T1D are glutamic acid decarboxylase
(GAD), insulin, islet-specific glucose-6-phosphatase catalytic subunit-related pro-
tein (IGRP) and insulinoma antigen-2 and 2β (IA-2 and IA-2β) [73, 74]. Under
normal circumstances, these self antigens remain hidden from the immune sys-
tem. However, in T1D, these autoantigens are exposed so that autoimmune
cells can become primed towards them and mount an autoimmune attack. It is
not known what triggers this exposure of autoantigens. However, genetic pre-
disposition, such as T1D susceptible MHC, and environmental factors, such as
infection [75], are thought to both be very important [76].
1.5.2. Infiltration and Insulitis
Following sensitisation to islet antigen, immune cells then begin to move into
the islets to form an infiltrate. First only the edges of the islets are affected and
this is known as peri-insulitis [77]. However, soon cells move into the islets too.
Infiltrating cells include, but are not restricted to, DCs, macrophages, B cells
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and T cells [78]. It is believed that insulitis is the point at which tolerance to β
cell antigen is lost [77]. There is evidence to suggest that this pathogenesis is not
limited only to the NOD mouse as pancreatic samples from diabetic humans
also reveal infiltrated islets. Similar to the NOD mouse, this infiltrate contains
CD8+ T cells, which have potential to become CTLs, other lymphocytes and
APCs [71].
1.5.3. β cell destruction
Following non-destructive insulitis, immune cells gain their aggressive traits
and β cells begin to be destroyed. The destruction of β cells in NOD and human
pancreatic islets is believed to be mediated by CTLs [71, 77, 78]. Only very few
insulin-producing β cells survive [6, 7].
1.6. B cell involvement in T1D
It has been found that B cells have a critical role in diabetes pathogenesis and
that without B cells, NOD mice are protected from the disease [79, 80]. However,
the role which these cells play in T1D pathogenesis is not known. The main
hypotheses relate to their two main physiological roles of antibody production
and antigen presentation, along with cytokine secretion [81]. However, there
is also potential that they are interefering with the process of T cell negative
selection which could also contribute to the disease process.
These potential roles will be discussed in more detail below.
1.6.1. B cells are important in T1D
Investigations into the role of B cells in T1D have revealed that the presence of
B cells is crucial for T1D onset.
Evidence for this came in 1996 when Serreze et al. [79] produced a mouse
protected from diabetes by genetically depleting B cells from the NOD mouse.
These mice retained normal T cell populations and all known diabetes suscept-
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ibility genes, but lacked B cells, suggesting that the diabetes protection resulted
from the lack of B cells. The resulting mouse was known as the NOD.Igµnull
mouse which had a functionally inactived Ig-µ chain (heavy chain) and, there-
fore, was unable to produce B cells. Further evidence came in 1997 when
Noorchashm et al. [80] used anti Ig-µ antibody to deplete B cells from female
NOD mice and compared the onset of insultis and blood glucose levels with
control NOD mice which received whole rabbit IgG (which controlled for the
process of antibody administration) and, therefore, retained their B cell popu-
lations. They found that insulitis and hyperglycaemia were not present in the
Ig-µ treated mice, but were present in the controls. Interestingly, they also found
that following removal of Ig-µ antibody, the B cell pool repopulated and insu-
litis returned, giving further evidence that insulitis and diabetes are linked to
B cell presence.
More recently, the importance of B cells in T1D pathogenesis has been shown
in both human diabetics and NOD mice through the effectiveness of B cell de-
pletion treatments in the prevention/delay of T1D onset. CD20 is expressed on
B cells and anti-CD20 monoclonal antibodies are able to bind to, and destroy B
cells [82]. Administration of anti-CD20 antibody during the early onset of T1D,
in both humans and mice, has an effect on slowing/preventing T1D progres-
sion. In man, it was found that Rituximab (an anti-CD20 antibody) treatment
in newly diagnosed type 1 diabetics preserved β cell function for a year fol-
lowing treatment before the disease progressed again [83]. In mouse models, it
has been shown that anti-CD20 antibody treatment can prevent or slow T1D
progression depending on the time point at which it is administered [84].
As yet, there is no definitive answer as to the role of B cells in T1D. However,
it is thought that it relates either to their antigen-presenting or autoantibody
producing functions, or both.
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1.6.2. Antibody production
Autoantibodies are present in T1D and have in fact been useful in identifying
candidate islet autoantigens [74]. However, the role that they play in the patho-
genesis of T1D is not known.
To assess the potential role of autoantibodies, autoantibodies from diabetic
NOD mice were transferred to NOD.Igµnull mice to see if diabetes susceptib-
ility could be transferred. However, there was no change in diabetes protection
so the mice remained disease free [85]. This gives the impression that, while
autoantibodies may be important in the disease, they are not sufficient to cause
disease onset and are not likely to be the primary role of B cells in the T1D
pathogenesis.
Further to this, the role of maternal autoantibodies in NOD offspring has been
investigated. Greeley et al. [86] has shown that the removal of insulin autoantibod-
ies from mothers of NOD offspring prevented T1D in offspring. However, oth-
ers, such as Koczwara et al. [87] have shown that maternal autoantibodies have
very little effect on the T1D progression in the offspring in NOD mice. This
shows that there is conflicting evidence for the role of autoantibodies in T1D.
The lack of clear cut evidence implicating autoantibodies as a major player in
T1D pathogenesis suggests that their production is unlikely to be the only role
of the B cell in T1D.
To assess the relative importance of autoantibody production versus antigen
presentation by B cells in T1D pathogenesis, Wong et al. [88] compared NOD.µMT
mice (mice that are unable to rearrange their IgM heavy chain and, therefore,
unable to progress beyond the pro B cell stage [89]) with transgenic mice that
were unable to secrete antibodies but still displayed a normal BcR. They found
that the transgenic mice had an increased incidence of T1D compared to the
NOD.µMT controls, suggesting that B cells drive T1D pathogenesis via an anti-
body independent mechanism [88].
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1.6.3. Antigen presentation
Following the finding that autoantibodies are not likely to be the principle
mechanism of action for B cells in T1D pathogenesis, Serreze et al. [85] looked
into the antigen presenting capacity of B cells. In particular, their ability to
present GAD and ellicit T cell responses was investigated. It was noted that
B cells were critical for the initial priming of T cells to GAD, shown by the
lack of spontaneous T cell response to it in NOD.Igµnull mice compared to con-
trol NODs. However, it seemed that following initial priming, other APCs were
sufficient to present to T cells on restimulation with GAD antigen. This could
explain why transfer of T cells from NOD mice into other mice lacking B cells
such as NOD/SCID mice (which have no T or B cells and are protected from
T1D) can cause disease, as APCs other than B cells in the recipient mice would
be sufficient to reactivate the transferred T cells [90].
B cells acting as APCs to activate autoreactive T cells was further investigated
by determining the effect of rendering B cells deficient of MHC Class II. In
this study, I-A g7 (the MHC Class II expressed in NOD mice [91]) expression
was deficient in B cells but normal on other non-B cell APCs [92]. These mice
were resistent to T1D, despite the presence of normal, non-B cell, APCs. This
suggests that it is a process relating to MHC Class II and, therefore, antigen
presentation, that B cells are required for.
B cell specificity to self antigen is important in T1D pathogenesis. Evidence for
this comes from the finding that T1D onset can be accelerated by modifying the
BcR to be more reactive to insulin. In this study by Hulbert et al. [93], B cells
were manipulated so that 1-3% of the B cell population were insulin specific.
Controls were also modified using similar transgenes but these gave limited
insulin binding capabilities. It was seen that the mice with insulin specific B
cells developed T1D at a much faster rate than controls, suggesting that antigen
specifity of B cells is an important determinant of T1D onset.
In terms of activating T cells, it is thought that CD8+ T cells are the main culprits
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for β cell destruction in T1D. As mentioned in Section 1.3.4, to activate CD8+
T cells, APCs have to present their cognate antigen on MHC Class I via the
process of cross-presentation. Whilst this process is usually carried out by DCs,
there is evidence that B cells can cross present islet antigen to CD8+ T cells
in the PLN. This was shown by a decrease in activated CD8+ T cell population
both in B cell deficient mice and in mice whose B cells have been rendered MHC
Class I deficient [94]. This gives the impression that B cells could be playing an
important role in activating CD8+ in the islets, allowing them to become CTLs
which could destroy β cells.
Further evidence for the activation of T cells by B cells is that NOD B cells
that have infiltrated the islets in T1D appear to have increased levels of cos-
timulatory molecules, B7-1 and B7-2 [95]. This could suggest that they have an
increased ability to present to, and activate, T cells which could aid the progres-
sion of the diabetic process in the islets.
The evidence to date suggests that presentation of self antigen to autoreactive
T cells is the principle action of B cells in the pathogenesis of T1D.
1.7. Thymic B cells
It is normal for small numbers of B cells to be present in the thymus of non
diabetic humans and mice [96–98]. However, in the NOD mouse, this popula-
tion of B cells is dramatically increased [85, 99]. It is not known how B cells
come to populate the thymus, it is thought to either be as a result of migration
to the thymus or development from progenitors within the thymus. Develop-
ment is more likely due to the fact that some thymic progenitors do have B cell
potential [40] and developing pro and pre B cells are seen in the thymus [96].
The increase in B cells is intriguing as it appears to be age-related and correlates
with the progression of the disease in the NOD mouse. This could suggest that
either thymic B cells are involved in driving the disease progression, or it may
be that they are a result of disease progression.
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This increase in thymic B cells is not entirely unique to T1D in NOD mice, it
is also a phenomenon seen in other autoimmune diseases such as myasthenia
gravis [100, 101] and, therefore, unravelling the origin and function of thymic
B cells in the NOD mouse, may have benefits beyond those in the field of T1D.
The function of thymic B cells is not known. It has been hypothesised that B
cells within the thymus may play a role in the negative selection of developing T
cells. Evidence of this has come from the discovery that thymic B cells position
themselves next to mTECs [102], are able to express AIRE [103] and that they
are able to delete T cell clones from the T cell repertoire by displaying self
anitgens [104]. However, these models utilise non-autoimmune prone mice that
have been manipulated to develop autoimmunity. It therefore remains to be
seen whether these hypotheses hold true in an autoimmune-prone model, such
as the NOD mouse.
1.8. Project Hypotheses and Aims
Figure 1.3 outlines the current understanding of B cell development in the bone
marrow, T cell development in the thymus and potential intrathymic B cell
development.
The importance of establishing the source of thymic B cells stems from the
increasing evidence that thymic B cells can manipulate central thymic tolerance,
and the finding of abnormally large populations of thymic B cells in disease-
prone NOD mice. This project aims to understand more fully the potential
pathway of intrathymic B cell development.
It is thought that B cells found in the thymus of NOD mice appear there due
to intrathymic development. Assuming this is the case, it is likely that these
B cells will be arising from undifferentiated progenitor cells which migrate to
the thymus with retained B cell potential. This forms the first project-driving
hypothesis that, within the thymus of NOD mice, it should be possible to see all
stages of B cell development from the very earliest committed B cell progenitor
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(the BLP), through pro, pre and immature B cell stages to mature B cells, if
development is occurring there. As well as seeing the different developmental
stages of B cells in the thymus, it is also hypothesised that there should be
evidence of B cell development milestones, in particular, BcR rearrangement,
within the thymic environment. Further to this, it is expected that findings in
young NOD mice will be different to older NOD mice, due to the strong age-
related nature of T1D disease progression. In particular, it is expected that the
intrathymic B cell development potential in the NOD mouse will change with
age.
In order to test the hypotheses outlined above, these are the main questions
that this project aims to investigate:
– Are early B cell progenitors and developing B cells present in the thymus of
NOD mice?
– Is the NOD thymus able to support B cell receptor rearrangement on devel-
oping thymic B cells and, if so, are these events age-related?
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Figure 1.3: B cells develop in bone marrow, T cells develop in thymus. In seeding of the thymus
with TSPs destined for the T cell fate, some progenitors may retain B cell poten-
tial. These cells may be differentiating into B cells in the thymus, resulting in a
population of thymic B cells. T cells go through negative selection in the thymus as
the first stage of tolerisation. Those which survive this process are released in the
periphery. In the case of T1D, healthy islets become infiltrated with immune cells in-
cluding T and B cells (potentially including some of thymic origin) and subsequently,
insulin-producing β cells are destroyed by CTLs. It may be that thymic B cells are
contributing to T cell negative selection in some way (black dashed arrow).
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Materials and Methods
2.1. Mice
NOD, NOD.µMT-/-, NOD-RAG2p-GFP, NOD.µMT-/-.RAG2p-GFP and C57BL/6
(B6) mice were used.
NOD.µMT-/- (hereafter referred to as NOD KO) mice are deficient in B cells and
have been described elsewhere [79]. They have a mutation in their IgM heavy
chain which prevents heavy chain rearrangement and subsequent progression
from the pro B cell stage to the pre B cell stage. This block in development
results in an inability to produce mature B cells and antibody secreting plasma
cells.
RAG2p-GFP reporter mice on a FVB background have also been described else-
where [105]. RAG2p-GFP reporter mice express green fluorescent protein (GFP)
under the control of the RAG promoter so that when RAG is expressed, so is
GFP. When RAG transcription is deactivated, so is GFP transcription. However,
the protein decays over time with a half life of approximately 56 hours [106],
meaning that GFP+ cells can be seen even after RAG deactivation.
For use in this project, FVB-RAG2p-GFP mice were backcrossed 12 generations
(N12) to the NOD mouse to produce NOD-RAG2p-GFP reporter mice (hereafter
referred to as NOD-RAG-GFP mice).
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NOD.µMT-/--RAG2p-GFP reporter mice (hereafter referred to as NOD KO-
RAG-GFP mice) were also used in this project. For this, N12 NOD-RAG2p-GFP
mice were crossed with NOD.µMT-/- mice. Heterozygous progeny were then
crossed back to NOD.µMT-/- mice. Mouse genotypes were determined by flow
cytometric analysis of blood samples to assess IgM and/or GFP presence.
All mice were housed in specific-pathogen-free barrier conditions at York Uni-
versity Biological Services Facility. All experimental procedures were conducted
under U.K. Government Home Office guidelines. For mouse studies, investig-
ations were carried out double or single blind, as stated in results, following
ARRIVE guidelines [107]
2.2. Cell preparation
2.2.1. Preparation from frozen tissue
Frozen immune cells housed at -80 °C in the Green Lab biobank, were quickly
defrosted by incubation in a waterbath at 37 °C. Defrosted cells were immedi-
ately resuspended in 5 mL phosphate buffered saline (PBS) supplemented with
0.5% bovine serum albumin (BSA) (hereafter referred to as 0.5% PBS/BSA) and
transferred to 15 mL tubes. Cells were then centrifuged for 3 minutes at 290
relative centrifugal force (rcf), supernatant discarded and the washing step was
repeated once more to ensure complete removal of the solution the cells had
been frozen in. The cells were then resuspended in 2 mL 0.5% PBS/BSA and
put in incubator at 37 °C, 5% CO2 for 2 hours to enable re-expression of cell-
surface molecules that had been downregulated due to the freezing process.
Cells then centrifuged as before, supernatant discarded and cells resuspended
in a volume appropriate for the subsequent procedure they were to be utilised
in.
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2.2.2. Preparation from fresh tissue
Freshly prepared cells were isolated from the thymus, spleen, inguinal lymph
nodes, pancreatic lymph nodes and bone marrow. For preparation of bone mar-
row cells, the femur and tibia were isolated and tissue gently removed using a
razor, leaving clean bone. The cells were isolated by flushing of femur and tibia
of mouse with 1 x PBS. For thymi and spleens, harvested tissues were homo-
genised using a seive and 2 mL syringe plunger. Lymph nodes were isolated
and placed in a petri dish containing 5 mL PBS. The cells were liberated by
grinding the tissue between two frosted glass slides. The cell suspensions were
centrifuged for 3 minutes at 290 rcf to pellet cells then the supernatant was
discarded. Where appropriate, red blood cells were lysed by resuspending cells
in 1 mL of water for 6 seconds, followed by 1 mL 2 x PBS to neutralise toxicity
of the water. The cells were then centrifuged as before, supernatant discarded
and the cells were resuspended as appropriate for subsequent procedure.
2.3. Flow cytometry
Single cell suspensions were prepared as in Section 2.2 and the cells were re-
suspended in 1 mL of 1 x PBS. 100 µL of cell suspension (equvalent to 106 to
107 cells) was then transferred to an appropriate vessel. The cells were incub-
ated with 1:300 dilution of anti-CD16/32 antibody and incubated for at least 10
minutes at 4 °C. This was carried out to block Fc receptors to avoid non spe-
cific binding of analytic antibodies used in the subsequent staining. The cells
were then stained using appropriate fluorescently labelled antibodies and in-
cubated for 25 minutes at 4 °C in the dark. Antibodies (from eBioscience or BD
Pharmingen) were used at 1:300 dilution, apart from anti-CD4 and anti-CD8
antibodies which were used at 1:800 dilution. The cells were washed in 3 mL 1
x PBS and centrifuged for 3 minutes at 290 rcf to remove unbound antibodies.
The supernatant was discarded then the cells were resuspended in 500 µL of 1
x PBS.
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Table 2.1: Antibody clones and suppliers
If biotin-conjugated antibodies were used, the dilution, incubation and washing
steps were conducted as above. Subsequently, fluorescent-labelled streptavidin
was added at 1:800 dilution in 1 x PBS and incubated for 20 mins at 4 °C.
Unbound streptavidin was removed by washing with 3 mL of 1 x PBS as above
and the cells were resuspended in 500 µL of 1 x PBS.
All antibodies used in this study were assessed and optimised for use against
isotype controls.
Data was acquired on a Dako CyAn™Flow Cytometer using Summit software
and analysed using FlowJo 7.6.1 software.
Antibody clones and suppliers are shown in Table 2.1.
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2.4. Magnetic cell sorting
2.4.1. Miltenyi beads and columns
The cells were prepared as in Section 2.2. For a cell lineage depletion, lineage
cell depletion kit (Miltenyi Biotech) was used. For separation of samples into
CD19+ and CD19- fractions, CD19 microbeads (Miltenyi Biotech) were used. For
both lineage depletion and CD19 separation, Miltenyi LS columns were used.
There were two deviations from the manufacturers protocol. Firstly, the addi-
tion of an Fc receptor-blocking step prior to the addition of the beads using
anti-CD16/32 antibody at 1:300 dilution. Secondly, the buffer used was 0.5%
PBS/BSA, rather than the buffer suggested in the protocol. Purity of the appro-
priate cells was verified by flow cytometric analysis. The cells were resuspended
in a volume of buffer appropriate for the procedure that they were to be used
in.
2.4.2. Qiagen BioMag goat anti-rat IgG beads
Cells were prepared as in Section 2.2 and resuspended in 500 µL of 0.5%
PBS/BSA. A 1:300 dilution of anti-CD16/32 antibody was added and samples
were incubated at 4 °C for 10 minutes to block Fc receptors. The cells were then
incubated with the appropriate purified antibodies depending on which cell
populations were to be depleted. Antibodies were added at appropriate con-
centrations and incubated for 20 minutes at 4 °C. 1 mL of BioMag goat anti-rat
IgG beads (Qiagen, 1mg/mL) were transferred to a 15 mL tube and 10 mL PBS
was added. The solution was placed on a magnet and left for approximately 10
minutes to allow the beads to adhere. A pasteur pipette was used to remove
the supernatant and the beads were resuspended in 500 µL of PBS. The beads
were put back on the magnet and allowed to adhere again before removing
supernatant as before. A final wash in 500 µL PBS performed then beads finally
resuspended in 500 µL PBS.
The cells were prepared by washing in 3 mL PBS and centrifuging for 10
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minutes at 290 rcf. The cell pellet was then resuspended with the 500 µL solu-
tion of beads and incubated for 15 minutes at 4 °C.
The samples were then placed on a magnet and beads allowed to adhere. Super-
natant containing unbound cells were removed with clean pasteur pipette, kept,
and put back on magnet to remove residual beads. The cellular supernatant was
isolated as before and centrifuged for 3 minutes at 290 rcf. The cells were then
resuspended in 500 µL 1 x PBS for subsequent flow cytometric analysis.
2.5. RNA preparation
Cells were prepared as in Section 2.2, then RNA extracted using RNeasy mini
kits (Qiagen) following the maunufacturers protocol. A DNAse step was in-
cluded where deoxyribonuclease I (Sigma) was added to the column membrane
for 10 minutes at room temperature. The addition of a DNAse step was to
prevent the binding of primers to residual genomic DNA. RNA quality was
assessed on the NanoDrop (ThermoScientific NanoDrop 2000), with the aim
of producing RNA with 260/280 and 260/230 values of near to, or above, 2.0
which indicates a good purity of RNA. RNA was resuspended in RNAse-free
water and stored at -80 °C.
2.6. Reverse transcription of RNA to cDNA
RNA was reverse transcribed to cDNA using Superscript II reverse transcriptase
(Invitrogen, 2000 U/µL). RNA was taken and heated at 55 °C for 10 minutes
before being placed on ice. 7 µL of first buffer (4 µL 5 x 1st strand buffer (Invit-
rogen), 2 µL 10mM dNTP mix (Thermo Scientific), 1 µL OligodT 0.5 µM (Invit-
rogen)) was added to 10 µL of RNA and the solution was placed in RNAse-free
PCR strips. Amount of RNA was normalised across samples using data from
NanoDrop in order to try and keep quantities of cDNA constant across samples.
The volume was then made up to 10 µL by the addition of RNAse-free water.
The samples were then incubated at 65 °C for 5 minutes to uncoil RNA, then
cooled quickly on ice. Three µL of a second buffer (1 µL 0.1M DTT, 1 µL RNAse
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out, 1 µL Superscript II (all Invitrogen)) was then added to each sample and
the solution incubated at 65 °C for 45-60 minutes to make cDNA. cDNA was
stored at -20 °C until needed.
2.7. Primer design
Specific primers for polymerase chain reaction (PCR) to look for B cell develop-
ment genes were designed using sequences derived from the National Center
for Biotechnology Information (NCBI) nucleotide database [108] then looking
for suitable primers for these genes using Primer3 (www.primer3.ut.ee) [109].
The primers were then put through a primer blast [110] to check for specificity
of the primer pair for the desired gene. Designed primers (obtained from Sigma
Genosys) were then tested to find their optimum annealing temperature by car-
rying out a temperature gradient PCR from 52-62 °C.
Primers are as follows:
– E2A. Forward TTG ACC CTA GCC GGA CAT AC. Reverse TGC CAA CAC
TGG TGT CTC TC. Expected product size: 150bp. Optimum annealing tem-
perature: 61.8 °C.
– EBF. Forward CAG TTC TGC AAA GGG ACA CC. Reverse CAA TGT CGG
CAG CTC TCT TC. Expected product size:226 bp. Optimum annealing tem-
perature: 59.4 °C.
– Pax5. Forward AAC TTG CCC ATC AAG GTG TC. Reverse CTG ATC TCC
CAG GCA AAC AT. Expected product size: 217bp. Optimum annealing
temperature 61.3 °C.
– VPreB. Forward CGA TAT CCC ACC TCG CTT CT. Reverse CCG AGC
AAA GCA AAC TCT GT. Expected product size: 238 bp. Optimum anneal-
ing temperature: 59.4 °C.
– CXCL12. Forward GCT CTG CAT CAG TGA CGG TA. Reverse TAA TTT
CGG GTC AAT GCA CA. Expected product size: 184 bp. Optimum anneal-
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ing temperature: 60.5 °C.
2.8. Polymerase chain reaction
Non quantitative polymerase chain reaction (PCR) was carried out to look for
the genes of interest using the primers outlined above. PCR samples consisted
of 1 µL cDNA, 1.125 µL forward primer, 1.125 µL reverse primer, 2.5 µL 25
mM MgCl2 (Applied Biosystems), 2.5 µL 25 mM Amplitaq360 buffer (Applied
Biosystems), 15.5 µL dH2O, 0.125 µL 250 U AmpliTaq 360 DNA Polymerase
(Applied Biosystems). cDNA was amplified following 35 cycles of 1 minute at
94 °C, 1 minute at the appropriate annealing temperature for the primer set, 1
minute at 72 °C. A final elongation step of 10 minutes at 72 °C was performed
once at the end of the 35 cycles. Amplified cDNA was subsequently analysed
by gel electrophoresis.
2.9. Gel electrophoresis
Gel electrophoresis of PCR products were carried out using 3% agarose gels
(Lonza SeaKem LE Agarose) made in 1 x Tris acetate-EDTA (TAE) buffer (Sigma)
supplemented with 1 µL of 10 mg/mL ethidium bromide (Sigma) per 25 mL
TAE buffer. 5 µL of 6x loading dye (Thermo Scientific) were added to each 25
µL PCR product sample. Total volume of 30 µL was then transferred to wells
in the gel, held in a gel rig containing 1 x TAE buffer. 100 base pair (bp) ladder
also put in a well of the gel to show size of bands seen in the gel. Gels were run
at constant 70 Volts until bands had separated sufficiently and imaged using
SynGene software.
2.10. Statistical Analyses
All graphs were drawn using GraphPad Prism and statistical analyses (One
way ANOVA, Tukey’s tests and Mann-Whitney tests) were performed using
built-in functions within the software.
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Results
3.1. B cells can develop intrathymically
3.1.1. B cell numbers in the NOD mouse thymus increase with age
As mentioned previously in Section 1.7, it is normal for a small population of
B cells, about 0.1-0.5% of thymocytes, to be present in the thymus of both hu-
mans and mice [102]. However, it has been noted by our lab (Varian and Green,
unpublished observations) and others [99], that this population is significantly
increased in NOD mice, compared to non diabetes prone control mice, such as
B6 mice. It is thought that these cells may have a role in the process of T cell
negative selection and, whilst some literature suggests this may be a beneficial
role [102, 104], it may be that in autoimmunity-prone mice, they are potentially
impeding central tolerance of T cells. For this reason, it is important to establish
when and why increased thymic B cells occur.
It is not clear whether the increased frequency of thymic B cells in NOD mice
compared to non-NOD mice is age-related; that is, whether or not the increased
population of thymic B cells correlates with a specific stage of the T1D process.
To confirm and extend our previous observations of the increase in thymic B
cells in NOD mice compared to control B6 mice, a time-course, flow cytometric
study was conducted. The time points for analysis were chosen to correlate
with different stages of the disease process in NOD mice (see Figure 1.2). As
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shown in Figure 3.1, as NOD mice age and progress along the T1D development
pathway, the frequency (Figure 3.1 A) and absolute numbers (Figure 3.1 B) of
mature thymic B cells increases significantly in comparison to control B6 mice
(Varian and Green, unpublished observations).
Thus, at 4 weeks - the time point in the disease pathway corresponding to prim-
ing of the autoreactive T cell repertoire to islet antigens occurs - no differences
were seen in either frequencies Figure 3.1 A or absolute numbers Figure 3.1 B
of mature IgM+ B cells in the two strains of mice. However, by 9 weeks of age,
when insulitis is well established and initial CTL activity to β cells is active,
there is a significant increase in both the frequency and absolute numbers of
thymic B cells in NOD mice with respect to control B6 mice. Furthermore, at 12
weeks of age - a time when β cell destruction is extensive and initial T1D devel-
opment is detectable in our colony - this disparity in thymic B cell frequencies
between the two strains of mice is even more prevalent.
Due to the interesting observation in the thymus, the bone marrow of NOD
mice was also investigated to determine if there is a similar age-related increase
in B cell frequencies in comparison to control B6 mice. To assess this possibility,
a time-course, flow cytometric study was carried out to look at the frequencies
of B cells in the bone marrow of NOD and B6 mice at the same time points as
the thymus time-course study. As shown in Figure 3.1 C, there is no significant
difference between the frequency of B cells in the NOD and B6 bone marrow at
any age. Furthermore, no significant difference in B cell frequencies were seen
in either spleen or lymph nodes of NOD and B6 mice (Data not shown). This
would suggest that the increase in B cells is specific to the thymus, not to the
mouse as a whole.
Finally, to assess whether this increase in thymic B cells impacted on the de-
velopment of the main T cell subtypes in the thymus, the frequencies of DN,
DP and SP T cells in NOD and B6 thymi were compared using flow cytometry.
Analysis of this data, shown in Figure 3.2, revealed that there was no significant
difference between NOD and B6 developing T cell populations at any age.
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Figure 3.1: B cell numbers in the NOD mouse thymus increase with age. Cells were isolated
from the thymus and bone marrow of NOD (n=3-4) and control B6 (n=3-6) mice
at the ages stated. The cells were incubated with anti-CD19 and -IgM antibodies
and the frequencies (A, C) and absolute numbers (B) of IgM+CD19+ mature B cells
in a live, single cell gate, was determined by flow cytometry. Statistical significance
in B cell populations between NOD and B6 mice was determined using the Mann
Whitney non-parametric test. The Mann Whitney test was used to compare the
difference in mature B cell frequency at each age. Differences between NOD and B6
were statistically significant at both 9 and 12 weeks of age (P=0.0190 and P=0.0040,
respectively). The difference at 4 weeks is not statistically significant. Black line
shows the mean and error bars show standard error of the mean. Acknowledgements
to Jennifer Varian for provision of raw data.
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Figure 3.2: The frequency of major T cell populations in the thymus of the NOD mouse are
the same as those seen in B6 control mice. Cells were isolated from the thymus of
NOD and B6 mice at the stated ages. Cells were subsequently incubated with anti-
CD4 and -CD8 antibodies for flow cytometric analysis. T cell subsets were identified
within a live, single cell gate. A shows 4 weeks of age (NOD n=3, B6 n=3), B shows
9 weeks of age (NOD n=3, B6 n=6) and C shows 12 weeks of age (NOD n=4, B6
n=8). Black line shows the mean and error bars show standard error of the mean.
Acknowledgements to Jennifer Varian for provision of raw data.
3.1.2. The NOD thymus contains B cell development transcription factors
If B cells are increasing within the thymus, this begs the question as to whether
the NOD thymus is providing an environment conducive to B cell development.
To try and answer the question of whether B cells are developing within the
thymus, rather than migrating there, primers were designed that were specific
for B cell development factors. If B cell development is occurring in the NOD
thymus, it would be expected that these development factors would be seen
in the there as they are a requirement for successful B cell development (see
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Section 1.4.2). Genes such as E2A, EBF, Pax5, VPreB and CXCL12 were chosen
as they are important for lineage commitment and/or lineage progession and
stabilisation (see Section 1.4.2). E2A is important for the formation of pro B cells
and is a requirement for the expression of EBF [23]. EBF is then important for
activating genes and transcription factors crucial for BcR rearrangement, such
as VPreB and FOXO1 [62]. Pax5 is important for the progression of progenitors
within the B cell lineage and for the repression of transcription factors driving
development of other lineages, for example, Notch1 for T cell development
[23, 64]. CXCL12 is a cytokine responsible for holding B cell progenitors in the
bone marrow niche during development [65].
Non-quantitative PCR was performed to compare whether or not B cell devel-
opment genes and transcription factors are present in the thymus of 11-12 week
old NOD mice. The bone marrow was included as a control tissue since this is
the normal site of B cell development. All transcription factors would be ex-
pected to be detectable in the bone marrow and this was the case, as shown
in Figure 3.3. Interestingly, all the genes, besides CXCL12 (Figure 3.3 E), were
also present in the NOD thymus too. This reinforces the idea that the thymic
environment is potentially able to support and/or promote B cell development.
The lack of CXCL12 in the thymus is not a surprising result as it is a cytokine
responsible for holding developing B cells in the bone marrow niche. Therefore,
it may be more bone marrow specific rather than B cell specific. This raises
the question as to what chemokine is holding developing B cells in the thymic
niche to enable completion of their development if it isn’t CXCL12.
It would be beneficial to carry out quantitative PCR to determine relative ex-
pression levels between the bone marrow and thymus of NOD mice, as non
quantitiative PCR can only indicate presence of a transcription factor. It would
also be useful to compare B6 control mice and NOD mice to see if the thymic
environments differed between the diabetes susceptible and non diabetic con-
trol mice. Unfortunately, due to time constraints it was not possible to carry out
quantitative PCR for this project.
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Figure 3.3: Non quantitative PCR reveals B cell development transcription factors are present
in the NOD thymus. RNA was prepared and reverse transcribed to cDNA. Non-
quantitative PCR was performed using primers specific for B cell development
transcription factors and genes. Gel electrophoresis was carried out to detect PCR
product. Gels were run in 3% agarose in 1 x TAE buffer. Gels were supplemented
with 1 µL ethidium bromide per 25 µL of 1 x TAE buffer. Gels were run at constant
70V. Lanes from left to right; Thymus, Bone marrow, 100 bp marker. 600bp mark is
indicated by the red arrow and box. The expected product size is shown by the blue
arrow and box. A: E2A; B: EBF; C: Pax5; D: VPreB; E: CXCL12. Mice analysed
were 12 weeks old.
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3.1.3. There are pro and pre B cells present in the NOD thymus
The mechanism by which B cell frequencies/numbers increase in the NOD
thymus is unknown. Two potential hypotheses to account for the increase are
development from progenitors entering the thymus which have B cell potential
[40, 96], or migration of B cells from the bone marrow. The current consensus is
that B cells are developing within the thymus and the data above would support
the hypothesis that the NOD mouse thymus may support B cell development.
To further investigate whether B cells are developing within the thymus, rather
than migrating there, we must first consider the different developmental stages
of the B cell (see Section 1.4.1 and Figure 1.1). The first of these stages is the
CD19+CD43+IgM- pro B cell stage. Subsequently, the IgM heavy chain is re-
arranged and coupled to a surrogate light chain (such as VPreB), forming
the preBCR. The sucessful formation of a preBCR allows progression to the
CD19+CD43-IgM- pre B cell stage. Next, the light chain rearranges resulting in
a full IgM molecule and the B cell can be released from the bone marrow to
migrate to the spleen to finish its development. An indicator of B cell develop-
ment within the thymus of the NOD mouse would be if these pro and pre B
cells are present in the thymus.
Akashi et al. [96] has shown pro and pre B cells in the thymus of B6 mice. It is
unclear whether similar populations occur in NOD mice, therefore, to determ-
ine this, a comparative flow cytometric study was carried out using NOD and
B6 mouse thymi. As a control, the populations of pro and pre B cells in the bone
marrow were also assessed, as this is the normal site of B cell development.
As shown in Figure 3.4 B, pro and pre B cells can be seen in the thymus of NOD
and B6 mice. The presence of pro and pre B cells suggests that these stages of B
cell development may be supported by the thymus. As expected, the bone mar-
row (Figure 3.4 C) also shows populations of pro and pre B cells which appear
similar between mouse strains. The gating strategy for revealing pro and pre B
cells in the bone marrow and thymi of NOD and B6 mice is shown in Figure 3.4
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A. The positions of the gates were decided by using the bone marrow as a tissue
control where clear populations of CD19+, IgM- cells could be seen. These gates
were then applied to the thymus. The divide between CD43+ and CD43- was
also determined by looking at bone marrow samples. Subsequent experiments
could also include isotype controls to show true negative populations for each
marker.
3.1.4. Thymic B cell development may be dependent on the presence of a mature B cell
The presence of pro and pre B cells in the thymus suggests that thymic B cell
development may occur in a similar manner to that occurring in the bone mar-
row.
In the bone marrow, progression from the pro B cell stage to the pre B cell
stage requires rearrangement of the IgM heavy chains. Ablation of IgM heavy
chain rearrangement results in blockade of pro to pre B cell stage, and as a con-
sequence an accumulation of pro B cells. To assess whether similar pro to pre
B cell transition is governed by IgM heavy chain rearrangment in the thymus,
comparative flow cytometric analysis of NOD mice with NOD KO mice (that
are unable to rearrange the IgM heavy chain, Section 2.1) was performed.
Comparative, flow cytometric studies of NOD and NOD KO bone marrow, as
expected, revealed that in NOD KO mice, B cell development was blocked at the
CD19+CD43+IgM- pro B cell stage (Figure 3.5 B). It was, therefore, expected that
in the NOD KO thymus there would also be a population of pro B cells, similar
to that seen in the thymus of NOD mice. However, this does not appear to be
the case. The gating quadrants shown in Figure 3.5 B were placed as shown
by looking at the picture in the NOD bone marrow which shows populations
of pro, pre and immature/mature B cells. These gates were then applied to the
NOD KO bone marrow and showed that the bone marrow showed only pro B
cells and lacked pre and immature/mature B cells. This gave the impression
that the gating was correct as literature relating to this mouse model states
that the B cell is unable to rearrange a IgM heavy chain Serreze et al. [79] and
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Figure 3.4: Pro and pre B cells are found in the thymus (B) and bone marrow (C) of both NOD
(n=3) and B6 (n=4) mice aged 6-9 weeks. Single cell suspensions were prepared and
incubated with anti-CD19, -IgM and -CD43 antibodies for flow cytometric analysis.
Pro (CD19+IgM-CD43+) and pre (CD19+IgM-CD43-) B cells within a live, CD19+,
IgM-, single cell gate were identified by flow cytometry. The gating strategy for both
thymic and bone marrow samples is shown in A by a representative thymic sample.
For the thymus, the cells were acquired on a CD19+ gate to enrich for B cells.
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therefore development should be stopped at the pro B cell stage. A method
to further validate the positioning of the gates would be to include isotype
controls in subsequent experiments to show true negative populations for each
marker.
When analysing this data, it was important to establish a gating system whereby
the two different strains could be compared fairly. NOD KO mice have no pre B
cells and no IgM+ cells. Therefore, previous gating to look at pro and pre B cells
(CD19+ then analysed on IgM and CD43 expression) would be skewed in the
NOD KO as 100% of the cells would be pro B cells - it would not be possible to
tell whether or not the population was increased or decreased with respect to
the other strains. With this in mind, IgM+ cells were gated out, as were CD43-.
This left only IgM-CD43+ cells, of which any that are CD19+ should be pro B
cells. This means that the frequencies of pro B cells can be compared fairly by
the frequency of CD19+ cells present within the IgM-CD43+ population. The
frequencies of pro B cells in both strains of mice are shown in Figure 3.5 C.
As shown in Figure 3.5 D, the frequency of pro B cells in the NOD KO mouse
thymus is significantly decreased in comparison to the frequency of pro B cells
in the NOD mouse thymus. This is an interesting finding as it suggests that the
enhancement of pro B cells in the thymus may be dependent on the presence
of a mature B cell.
3.1.5. Mature NOD thymic B cells are killed following transfer into NOD KO recipients
The finding that the frequency of pro B cells was decreased in NOD KO mice
with respect to NOD mice (Figure 3.5), suggests that mature B cell presence
may influence thymic B cell development. However, it is not known whether
these potential effects are due to peripheral or thymic resident B cells. In order
to investigate the role of thymic B cells in general, and in particular, determine
whether or not they have an effect on the pro B cell population seen in the
thymus a suitable experimental approach would need to be decided upon first.
A potential approach would be to transfer mature thymic B cells from NOD
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Figure 3.5: NOD mice have an increased frequency of thymic pro B cells compared to NOD
KO mice. Single cell suspensions were prepared from 6-8 week old NOD (n=3) and
NOD KO (n=4) mouse thymi and subsequently incubated with appropriate analytic
fluorescent-labelled antibody for flowcytometric analysis. B shows a representative
FACS plot of NOD and NOD KO bone marrow gated on CD19+, live, single cells.
Thymic samples were gated on acquisition for CD19+ cells. CD19+ pro B cells were
identified in the thymus of NOD and NOD KO mice (C) from CD43+IgM+ cells
in a live, single cell gate; the gating strategy for which is shown in A. D shows the
frequencies of pro B cells in NOD and NOD KO thymi. Statistical significance was
determined using an unpaired T test. P=0.0004 (P<0.05 is deemed significant). The
black line shows the average frquency and the error bars represent the standard error
of the mean. Data shown are from one experiment that has been repeated 5 times.
A total of 32 mice were examined. Experiment was carried out single blind to avoid
bias.
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donors into NOD KO recipients. A similar approach has been tried by Serreze
et al. [85] which resulted in CTL destruction of the transferred B cells, suggest-
ing that this approach may not work. However, Serreze et al. [85] transferred
splenic B cells rather than thymic B cells and since the properties of thymic B
cells are not well understood, it is not clear whether thymic B cells would be
similarly susceptible to death in NOD KO mice.
To investigate this, a pilot study was performed whereby thymic cells, including
thymic B cells, were isolated from NOD mice and transferred into NOD KO
mice, to see whether they could survive in the NOD KO recipients.
Due to the preliminary nature of the transfer experiment, very small numbers of
mice were used. Ten week old female donor NOD and recipient NOD KO mice
were used. At 10 weeks of age, numbers of thymic B cells are high in the NOD
thymus enabling sufficient numbers for isolation and transfer. The experimental
plan for the transfer experiment is outlined in Figure 3.6 A. Thymocytes were
prepared from two donor mice and CD19+ and CD19- populations separated
using magnetic bead assisted cell sorting. This approach yielded a thymocyte
fraction enriched for CD19+ cells (CD19+ fraction) and a thymocyte fraction
largely devoid of CD19+ cells (CD19- fraction). The purity of the two cellular
fractions in terms of B cell presence/absence was determined by flow cytometry
(see Figure 3.6 B).
The donor populations were transferred by intravenous injection into the recip-
ient mice, then recipient tissues were analysed by flow cytometry at the stated
time points. As shown in Figure 3.7, flow cytometric analysis revealed that ma-
ture B cells (CD19+IgM+) were only present in the recipient mice at the 7 day
post transfer time point. The inability to detect mature B cells at the later, 11 day
timepoint, may reflect cytotoxic killing of these cells in NOD KO mice [85]. At
either time point, no mature B cells were detectable in the bone marrow or any
lymph node analysed (Data not shown). In contrast, both the spleen Figure 3.7
A and thymus Figure 3.7 B of recipient NOD KO mice contained mature B cells
at the 7 day time point.
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AB C
Figure 3.6: Experimental setup and donor cell populations for transfer experiments. A shows a
diagram of the experimental setup. B shows the efficiencies of the MACS separations
carried out. Mature IgM+B220+ B cells were identified within a live, single cell gate
for both the CD19+ and CD19- fractions. C shows the total thymic cell counts of the
donor mice along with the frequencies of mature B cells. Also shown is the number
of B cells transferred into the recipient mice for each fraction.
62
Although B cells are seen in the thymus and spleen of both recipients at the 7
day time point, it seems that there is a higher frequency of CD19+IgM+ cells in
the recipients that received the CD19+ cell containing donor cells. This finding
is not surprising as this recipient received more mature B cells in the transferred
cells.
In the CD19- recipients, there are also mature B cells present in the spleen and
thymus at the 7 day time point. The population in the spleen could reflect con-
taminating B cells which were transferred. It is unlikely that these B cells seen
have developed from CD19- progenitors due to B cells not normally developing
in the spleen. However, while the population of B cells in the thymus could also
be due to contaminating transferred B cells, it may be that within the thymus,
there is the potential for CD19- B cell progenitors to develop into mature B cells
there.
The aim of the experiment was to look at the lifespan of B cells following trans-
fer into recipient NOD KO mice, to see if this would be a viable method for
investigating the effect of mature B cells on thymic pro B cell frequency. How-
ever, it has shown that this methodology is not appropriate for these investiga-
tions due to the disappearance of transferred cells between 7 and 11 days post
transfer. Future studies in which recipient NOD KO mice are first sublethally
irradiated and subsequently transfused with bone marrow from NOD KO mice
supplemented with mature thymic B cells [85], may offer a more successful
approach. By using this approach, it should mean that endogenous T cells are
developing in the presence of B cells and should, therefore, become tolerised to
them. This, in turn, should prevent any CTL-mediated B cell destruction occur-
ring during transfer and allow the effects of thymic B cells on thymic pro B cell
populations to be investigated.
3.1.6. The NOD thymus can support BcR rearrangement
Initial rearrangement of the BcR takes place at the pro to pre B cell transition
phase, and the finding that pre B cells are present in the NOD thymus suggests
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A: Spleen
B: Thymus
Figure 3.7: Donor B cells are found in the spleen and thymus of recipient mice at 4 days post
transplant. Cells were isolated from the recipient bone marrow, thymus, spleen, PLN
and axillary lymph node and incubated with anti-CD19 and -IgM antibodies for flow
cytometric analysis. Thymic samples were gated on acquisition for CD19+ cells. For
analysis, mature CD19+IgM+ B cells were identified within a live, single cell gate.
A shows the spleen and B shows the thymus from both recipients and both time
points, as stated. Spleen, PLN and axillary lymph node data not shown. n=1 for
each type of recipient. The experiment was carried out double blind to avoid bias
during analysis.
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that the thymus can support early rearrangments of the BcR. To confirm this,
NOD-RAG-GFP reporter mice were utilised to look for RAG expression by
developing thymic B cells. If RAG is being expressed by CD19+ cells in the
thymus, this gives more definitive evidence that B cells are developing in the
thymus, rather than just relying on seeing cells with the phenotypes of pro and
pre B cells.
NOD-RAG-GFP reporter mice express GFP under the control of the RAG pro-
moter, therefore, during receptor rearrangement when RAG is being transcribed,
GFP is also produced and can act as a marker for RAG activity. Further to
this, while transcription of RAG and GFP cease simultaneously, GFP degrades
slowly over time with a half life of approximately 56 hours in vivo [106]. This
means that the intensity of GFP signal seen on flow cytometry correlates with
how recently RAG/GFP transcription was active. For example, as shown in Fig-
ure 3.8 B, the GFPhigh population in the bone marrow represents the develop-
ing B cells which are actively rearranging their receptor. The GFPlow population
shows the cells that have recently rearranged their receptor and subsequently
deactivated RAG/GFP transcription, therefore, the GFP signal is decreased. The
GFP- population represents cells which rearranged their receptor more than 56
hours previously.
Murine strains of RAG-GFP reporter mice have been invaluable at document-
ing the differing frequencies of developing, newly developed and long term
resident thymic T regulatory cells depending on co-stimulatory signals [111].
Thus, NOD-RAG-GFP mice enabled analysis not only of BcR rearrangment in
developing B cell populations, but also the proportion of developing, newly
developed and long term resident thymic B cells.
To investigate whether the thymus may be able to support BcR rearrangement,
depending on the stage of the disease, cells of the B cell lineage were iden-
tified by expression of CD19 then these cells were interrogated for their GFP
expression. As shown in Figure 3.8 A, there are CD19+GFPhigh cells within the
thymus of NOD mice at 4, 7 and 11 weeks of age. This finding confirms that
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the NOD thymus supports rearrangment of the NOD BcR, as no CD19+GFP+
cells would be detectable if it did not. Further to this, as shown in Figure D, in-
terestingly, it appears that the frequency of CD19+GFP+ cells decreases as mice
progress through the T1D process. In particular, the frequency of CD19+GFPlow
cells decreases significantly between 4 and 11 weeks of age. Conversely, the fre-
quency of the CD19+GFP- increases significantly between 4 and 7 weeks of age.
The significant decrease in CD19+GFPlow cells in the NOD thymus could show
that there is a decreased frequency of newly developed B cells in the thymus
of older NOD mice. This could be due to a decrease in B cell development, or
increased emigration of newly developed B cells. This is an interesting result as
it could suggest that the support of early BcR rearrangement in the thymus is
limited to younger mice.
3.1.7. Early B cell progenitors are present in the thymus of NOD and B6 mice
As shown in Figure 3.1 A, there is an age-related, significant increase in thymic
B cells in NOD mice compared to B6 control mice that do not develop T1D.
The age-related increase correlates with the onset of insulitis in NOD mice and
increased activity of autoreactive T cells. Given this differences between NOD
and B6 mice, and the evidence that B cell development is supported in the
thymus, the question arose as to whether thymic seeding progenitor cells with
B cell potential are present within the NOD thymus at higher frequencies than
control B6 mice.
To investigate this, it was important to first of all decide on the specific pro-
genitor that would be looked for. Although the B cell commitment pathway
remains undefined, as mentioned in Section 1.4.1, it appears that a so-called
BLP may be the best described B cell progenitor. In which case, the cells of
interest would be Sca-1low c-kitlow Flt3+ IL-7Ra+ Ly6D+ [49–51] (See Figure 1.1).
However, the matter was complicated further due to the fact research into B cell
commitment and development is focussed on B cell development in the bone
marrow. Research into the development of B cells in the thymus, therefore,
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Figure 3.8: Some CD19+ cells in the NOD thymus express RAG. Cells from the bone marrow
and thymus were isolated from NOD-RAG-GFP mice and incubated with anti-CD19
antibody for flow cytometric analysis. Thymic samples were gated on acquisition for
CD19+ cells to enrich for B cells. For analysis, GFPhigh, GFPlow and GFP- CD19+
cells were identified within a live, single cell gate. This data is shown in A. Equi-
valent data is shown for the bone marrow in B. Gates were set for thymic RAG
expression using the RAG expression levels in the total thymic sample shown in C.
The difference in RAG expression at the different ages is shown in D. Statistical signi-
ficance was determined using one-way ANOVA and post hoc Tukey’s test. P<0.0001
(P<0.05 is deemed significant) for both GFPhigh and GFPlow CD19+ cells. Black
line represents average frequency. Data shown are representative of all 14 mice that
were examined.
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requires the assumption that the developmental pattern will match that of the
bone marrow. While it is not known how well the developmental pattern in the
thymus mirrors that of the bone marrow, it is a good place to start due to the
wealth of literature relating the B cell development in the bone marrow.
The aim of the investigations was to determine whether or not the frequencies
of BLPs in the NOD mouse were the same as that seen in the control B6 mice
and in the NOD KO mice. This would give insight into two areas. Firstly, if
NOD mice have an increased frequency of B cell progenitors in their thymus
compared to B6 mice, this could potentially explain the increased number of
B cells in the NOD thymus. And secondly the analysis could ask if BLPs are
affected in the same way as pro B cells by the presence or absence of a mature
B cell. This would be shown by a decreased frequency of BLPs in the NOD KO
compared to the NOD.
For these studies, all mice used were 6-8 weeks of age, a time point that correl-
ates with the onset of increased accumulation of thymic B cells in NOD mice,
with respect to control B6 mice.
Due to the small size of progenitor populations in comparison to mature cell
populations in the thymus, it was first necessary to deplete the thymus of the
majority of mature cells before looking for progenitors. For depletion, magnetic-
activated cell sorting (MACS) was used. There are different MACS-based ap-
proaches to enrich for progenitor cells. The decision of which approach to use
was taken after investigating the purity and yield of lineage negative cells fol-
lowing separation using Miltenyi lineage-depletion kits or Qiagen BioMag goat
anti-rat beads combined with our own anti-lineage antibody cocktail (see Sec-
tion 2.4).
Firstly, Miltenyi columns and lineage depletion beads were tested to assess
their efficiency. To start with, only one round of depletion was carried out but
the depletion was not complete enough, therefore, two rounds of depletion
were carried out. This improved the efficiency, however, the yield was very low
meaning that very few cells were left to analyse (data not shown).
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Figure 3.9: Flow cytometric analysis of lineage depletion using Qiagen beads. Thymic cells were
isolated from NOD mice and incubated with purified anti-CD4, -CD8 and -CD19
antibodies. Mature T and B cells were then removed using Qiagen BioMag goat
anti-rat beads and a magnet. Lineage depleted samples were then incubated with
fluorescently labelled anti-CD4 and -CD8 antibodies, of a different clone to those
used for depletion, along with anti-B220. Flow cytometric analysis was carried out
to determine lineage depletion efficacy. CD4- CD8- B220- cells were identified as
shown, within a live, single cell gate. Data shown is representative of the 7 mice
examined.
Qiagen BioMag goat anti-rat beads were also tested as an alternative to the
Miltenyi kits. As shown in Figure 3.9, the efficiency of this method was also
very good and the yield was also much improved compared to the Miltenyi
beads therefore this was the chosen method of depletion.
In order to assess the frequency of BLPs present in the thymus of NOD, NOD
KO and B6 mice, it was first necessary to establish a suitable gating strategy.
Firstly, data was gated to find the CLP population within the thymus. For this
a lymphocyte and single cell gate was applied then data was gated to anaylse
only cells which were Sca-1lowc-kitlowFlt3+IL-7Rα+. From this population, it is
then possible to determine which of these cells are BLPs and, therefore, likely to
be B cell committed, depending on their Ly6D expression. This gating pattern
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is shown in Figure 3.10 A.
When examining the frequencies of BLPs within the thymic CLP population, it
appeared that BLPs are present in the thymus of all strains of mice. However,
interestingly, the frequency of BLPs in the thymic CLP population was signific-
antly decreased in NOD and NOD KO mice compared to control B6 mice, as
shown in Figure 3.10 B.
The presence of BLPs in the B6 thymus could suggest that they are the normal
progenitor for the normal population of thymic B cells seen in nondiabetic
animals. The significant difference in BLP frequencies between NOD mouse
strains and control B6 mice may suggest that in NOD mice, thymic B cells
originate from an alternative progentitor or developmental pathway.
Further to this, the presence of a mature B cell does not appear to have an
impact on the frequency of BLPs in NOD mice of this age, as shown by the
similarity in BLP frequency between NOD and NOD KO mouse thymi.
Finally, to confirm that BLP frequency was independent of mature B cell pres-
ence, a further group of NOD and NOD KO mice were assessed at 12-13 weeks
of age, a time point when thymic B cell numbers peak in the NOD mouse. Un-
fortunately, no control B6 mice were available at this age to be included in the
analysis. As shown in Figure 3.11, there is no difference in the frequency of
Ly6D+ BLPs within the CLP population. This may suggest that the action of a
mature B cell to increase the pro B cell population in B cell sufficient mice, as
opposed to B cell deficient mice, is after the BLP stage. However, the spread
of data for NOD KO mice is much greater than for the NOD mice, therefore,
further repeats would be beneficial.
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Figure 3.10: BLPs are significantly decreased in the NOD mouse thymus compared to the B6
mouse thymus. Thymic cells were isolated from 6-8 week old NOD (n=3), NOD KO
(n=3) and B6 (n=4) and depleted of mature B and T cells by MACS using purified
anti-CD4, -CD8 and -CD19 antibodies and Qiagen BioMag goat anti-rat beads.
Samples were then incubated with fluorescently labelled analytic anti-CD4, -CD8
(of different clones to those used for lineage depletion), -Sca-1, -c-kit, -Flt3, -IL-7Rα
and -Ly6D for flow cytometric analysis. For analysis, BLPs were identified as Ly6D+
cells within a live, single cell, CD4-, CD8-, Sca-1int, c-kitint, Flt3+, IL-7Rα+ gate.
This gating pattern is shown in A (live, single cell, CD4-CD8+ gating not shown).
The difference in frequency of BLPs in the different strains of mouse is shown in B.
Statistical significance was determined using one-way ANOVA (P=0.0003) and post
hoc Tukey’s test. Black line shows the mean and error bars show standard error of
the mean. Data are representative of one experiment where 11 mice were examined.
The experiment was carried out single blind to avoid bias during analysis.
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Figure 3.11: The frequency of thymic BLPs is the same in both NOD and NOD KO thymi.
Thymic cells were obtained from NOD (n=5) and NOD KO (n=5) thymi. Prepar-
ation and staining was the same as samples in Figure 3.10 Statistical significance
was assessed using the Mann Whitney test but the difference between the NOD
and NOD KO thymic BLP frequency was found to be not significant. Black line
shows the mean and error bars show standard error of the mean.
3.2. Some RAG+ cells in the thymus express B and T cell markers
B cells normally develop from progenitor BLPs in the bone marrow. Therefore,
initially, BLPs were looked for in the NOD thymus to assess whether or not
the normal B cell developmental pattern could be seen in the thymus. However,
following the results suggesting that NOD thymi may have less thymic BLPs
compared to the control B6 mice (Figure 3.10 B), an increase in early B cell
progenitors is unlikely to account for the increase in thymic B cells in the NOD.
This would suggest that there is an alternative pathway of B cell development
in the thymus that is different to the pathway seen in the bone marrow.
3.2.1. A large proportion of RAG+CD19+ cells in the NOD thymus express CD4 and CD8
During the course of study, in-depth phenotyping of GFP+ cells in the thymus
revealed a surprising finding that CD19+ GFP+ cells expressed CD4 and CD8
T cell markers. It was decided to follow up this preliminary observation by
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determining whether there may be a point where thymocytes are not yet fully
lineage committed and are expressing markers of both T (CD4, CD8) and B
(CD19) cells.
To investigate this, time course flow cytometric studies of the thymus, or control
bone marrow, using 4 and 7 week old NOD-RAG-GFP mice were performed.
Mice of 4 and 7 weeks of age were analysed and a representative FACS plot
of a 4 week old NOD thymus and bone marrow are shown in Figure 3.12.
Here, the difference between the thymus (Figure 3.12 A) and bone marrow
(Figure 3.12 B) is shown. As shown in Figure 3.12 A, approximately 69.2%
of thymic GFPhighCD19+ cells also co-expressed CD4 and CD8 molecules. In
contrast, only approximately 5.14% of GFP-CD19+ cells also co-expressed these
T cell markers. This uniqueness for GFPhigh CD19+ cells to co-express CD4 and
CD8 molecules was restricted to the thymus, as similar analysis of both the bone
marrow and spleen revealed 0.016% (Figure 3.12 B) and 0.38% (Figure 3.12 C)
of GFP+CD19+ cells co-express CD4 and CD8 molecules, respectively.
The lack of RAGhighCD19+CD4+CD8+ cells in the bone marrow suggests it is
unlikely that these cells are a normal part of B cell development (Figure 3.12
B). It is also unlikely that they are a normal part of T cell development as T cell
commitment is thought to occur fully in the DN development stage, therefore
when developing T cells are still CD4-CD8-.
This suggests that they are thymus specific and it may highlight another abnor-
mality within the NOD thymus that may or may not be related to the increased
population of thymic B cells. It could potentially suggest an alternative mech-
anism by which B cells are increased in the NOD thymus. It may be that a cell
is beginning to commit to the T cell lineage, then at some point receiving a
signal which is causing it to begin switching lineages and start expressing B
cell markers. These cells could then potentially redifferentiate fully into B cells.
This potential redifferentiation could explain the existence of both B and T cell
markers on the cells, and account for the decreased frequency of conventional
B cell markers in the NOD mouse thymus compared to the B6 control thymus.
73
However, further research would be required to explore this further.
These RAGhighCD19+CD4+CD8+ cells are present in the thymus of NOD mice
at both 4 and 7 weeks of age. As shown in Figure 3.12 E, the difference in
frequency of these cells between the thymus and bone marrow is statistically
significant at both ages. However, it was found that there was no significant dif-
ference in frequency of RAGhighCD19+CD4+CD8+ cells in the thymus between
4 and 7 weeks of age (P=0.3429).
3.2.2. RAG+IgM+TcRβ+ cells are present in the NOD thymus
While GFP+CD19+CD4+CD8+ cells could potentially be lymphocytes transition-
ing from one lineage to another, this is not the only hypothesis relating to these
cells. It may be that a developing T or B cell starts to receive signals which
cause it to express markers of both the T and B cell lineage. If this is the case,
it was wondered whether this cell would continue development and eventually
co-express the receptors for both lineages. To test this hypothesis, IgM+TcRβ+
cells were looked for in the NOD thymus.
As shown in Figure 3.13, it appears that there is a small population (0.440%) of
RAG+IgM+TcRβ+ in the thymi of NOD mice. Bone marrow preparations were
included as a control and, as shown in Figure 3.13 B, there are no IgM+TcRβ+
present there. The difference in frequency of IgM+TcRβ+ cells between the bone
marrow and thymus is statistically significant, as shown in Figure 3.13 C.
It may be that RAG+IgM+TcRβ+ cells are mature cells that develop from RAG+CD19+CD4+CD8+
cells seen in the thymus. However, the data presented cannot link the two pop-
ulations. It may be that the two populations are totally separate from each other
and represent two different populations found in the NOD thymus. More in-
vestigation into these cells in both diabetes-prone and diabetes-resistant mice
is warranted.
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Figure 3.12: There are GFP+CD19+CD4+CD8+ cells present in the NOD thymus. Cells were
isolated from the thymus, bone marrow and spleen of 4 (n=5) and 7 (n=4) week old
NOD mice. Cells were incubated with anti-CD19, -CD4 and -CD8 antibodies for
flow cytometric analysis. Thymic samples were gated on acquistion for CD19+ cells.
Firstly a live, single cell gate was applied (not shown) then the gating pattern shown
in A was used to identify CD4+CD8+CD19+ in GFP+ and GFP- populations. CD4
and CD8 gates were set using normal thymic T cell populations as a control, as
shown in D A representative FACS plot of GFP+CD4+CD8+CD19+ cells in the
NOD mouse BM (B) and spleen (C) is also shown following application of the
gating shown in A. Frequencies of GFP+CD4+CD8+CD19+ in NOD mouse thymi
and bone marrow at 4 and 7 weeks of age is shown in E. Statistical significance
between frequencies in the thymus and bone marrow was determined using the
Mann Whitney test. 4 weeks, P=0.0108; 7 weeks P=0.0151 (P<0.05 is deemed
significant). Black line shows the mean and error bars show standard error of the
mean. Data is representative of all 9 mice examined.
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Figure 3.13: There is a small population of GFP+IgM+TcRβ+ cells in the NOD thymus. Cells
were isolated from the thymus and bone marrow of 11 week old NOD-RAG-GFP
(n=3) incubated with anti-CD19, -IgM and -TcR antibodies and analysed by flow
cytometry. Thymic samples were gated on acquistition for CD19+ cells. For ana-
lysis, IgM+TcRβ+ cells were identified within a live, single cell, GFP+ gate. Gat-
ing strategy shown in A. Representative FACS plots showing presence/absence of
IgM+TcRβ+ for the NOD thymus and bone marrow are shown in B. C shows the
frequencies of GFP+IgM+TcRβ+ cells in the NOD thymus and bone marrow. Stat-
istical significance in frequencies between the two tissues was determined using an
unpaired T test and found to be significant, P=0.0206 (P<0.05 is deemed to be
significant). Black line shows the average frequency and the error bars represent
the standard error of the mean. Data shown are from one experiment which has
been repeated twice. A total of 8 mice were examined. The experiment was carried
out single blind to avoid bias.
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Discussion
Type 1 diabetes is believed to be due, in part, to a breakdown in central toler-
ance of T cells in the thymus. Our studies, and others, have correlated a signi-
ficant increase in thymic B cells in NOD mice, with respect to diabetes-resistant
murine strains, with T1D progression to the β cell destruction phase. The origin
and role of these B cells are not known, but they might possibly be involved
in the breakdown of central tolerance. Due to the strong correlation between
thymic B cell numbers and T1D susceptibility, it is important to establish how
intrathymic abnormalities occur in NOD mice. This project aims to investigate
more fully the potential intrathymic development of B cells.
Through this project, it has been confirmed that B cells are increased in the
NOD mouse thymus with respect to B6 control mice, and that this increase is
age-related. In terms of potential intrathymic development, it has been shown
that the thymus contains B cell development transcription factors and, there-
fore, could be conducive to B cell development. Also, pro and pre B cells are
present in the thymus of NOD mice, though the population frequency appears
to be dependent on the presence of a mature B cell. Further to this, there is
evidence of active B cell receptor rearrangement in the thymus, indicative of
active B cell development. However, the progenitor from which thymic B cells
are originating from is less clear. Whilst BLPs are present in both NOD and B6
mouse thymi, they are significantly decreased in the NOD mouse compared to
B6 mouse suggesting an alternative progenitor for thymic B cells, at least in the
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NOD mouse.
Also, further to these findings, there were some interesting results which sug-
gested the presence of a cell in the thymus expressing markers of both T and
B cells, and in fact a small population expressing both a B and T cell receptor.
These could provide an alternative mechanism for B cell development through
re-differentiation of T cells.
4.1. There is an age-related increase in thymic B cells in the NOD mouse
The results showing an age-related increase in thymic B cells in the NOD mouse
compared to the B6 control mouse suggests there may be a correlation between
thymic B cells and T1D progression. T1D onset occurs with initial priming of
T cells between 3-5 weeks of age. At this point there is minimal responsiveness
of T cells to T1D antigens and the population of B cells in the NOD thymus
is not increased compared to control B6 mice. At 5 weeks of age, the islets
start to become infiltrated with immune cells and by 9 weeks, CTL mediated β
cell destruction is initiated and progresses to destroy the majority of β cells. In
terms of thymic B cell numbers, B cells are significantly increased at 9 weeks of
age in NOD mice compared to B6, and further increased by 12 weeks.
T cell development and education occurs within the thymus, in particular the
first step of T cell tolerisation, negative selection. This is where autoreactive T
cells are purged from the repertoire to prevent potential autoimmunity [112].
T1D is believed to be due to a breakdown in tolerance and, therefore, it may
be that B cells found in the thymus of NOD mice may be contributing to this
process. There is evidence that B cells are able to contribute to the process of
negative selection, as shown by Frommer and Waisman [104] and Yamano et al.
[103]. Yamano et al. [103] have demonstrated that B cells found in the thymus,
but not the periphery, are able to express AIRE, similar to mTECS which clas-
sically mediate negative selection. Using AIRE-reporter mice, donor splenic B
cells were transferred into recipient mice then the thymi of the recipient mice
were analysed one week after transfer. It was observed that there were AIRE
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expressing donor cells in the thymus of the recipient mice. This suggests that
there may be something in the thymic environment which is causing B cells to
express AIRE upon entering the thymus. MHC class II, also important for me-
diation of negative selection, was also upregulated on the immigrating thymic
B cells. Meanwhile, Frommer and Waisman [104] utilised a mouse that specific-
ally expressed myelin oligodendrocyte glycoprotein (MOG) on MHC class II of
all B cells, including thymic B cells (BMOG mice). These mice were then crossed
with a transgenic mouse with has a T cell repertoire specific for MOG (2D2
mice). Interestingly, in the resulting mice (BMOG/2D2 mice), the frequency of
CD4+ T cells was significantly reduced in the thymus and periphery, compared
to 2D2 mouse controls. After ruling out the possibility of mTECs and other
APCs in the thymus expressing the MOG antigen and, therefore, contributing
to the negative selection of the MOG specific T cells, it was shown that the dele-
tion of MOG specific T cells in the thymus was as a result of MOG expression
on MHC Class II of B cells.
In the above studies, non-autoimmune prone mice were utilised in which the
autoimmune process was inititated by inducing the inappropriate expression
of host antigens and biasing the T cell repertoire to recognise these antigens. In
these cases, the role of the B cells in the thymus appeared to be beneficial to the
host in the tolerance induction in developing T cells. However, it is plausable
that in autoimmune prone mice, such as the NOD mouse, the B cells may, in
fact, be detrimental to the negative selection of T cells. It could be that thymic
B cells are a driving force in the breakdown of negative selection, and that the
increase in thymic B cells seen in the NOD thymus, compared to control B6
mice, is linked to an increasing breakdown in negative selection. On the other
hand, as previous literature suggests that the negative selection provided by
thymic B cells is beneficial in T cell education, it may be that increased thymic
B cells are a consequence of the disease process, such that their development
is triggered to help with an increasing population of developing autoreactive T
cells.
Investigation into the role of thymic B cells was outside the remit of this project
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but it remains a fundamental area that neccessitates further research in the
future.
4.2. B cells are developing intrathymically
Thymic pro and pre B cell presence
The main hypotheses for the origins of thymic B cells are (a) intrathymic de-
velopment from progenitors, or (b) migration of B cells from the bone marrow
to the thymus. The general consensus is that B cells are developing within
the thymus with very little contribution from the circulation. Experiments in-
volving parabiotic congenic mice (where two congenic mice share the same
blood system) showed that of the thymic B cells, the majority were of the en-
dogenous phenotype, not the parabiotic partner. This gave the impression that
the presence of thymic B cells have more to do with the signals within the
thymus itself, rather than alteration in the circulation pattern of B cells [102].
Similarly, Akashi et al. [96] found that the majority of thymic B cells were of
host origin. To investigate this, donor adult (Ly5.1 x Ly5.2)F1 mouse splenic B
cells were injected into Ly5.1 recipient mice. The percentages of B cells of donor-
and recipient-derived B cells were then evaluated in the thymus and periphery
of the recipient mice. In the periphery, approximately 5-7% of B cells were of
donor origin, compared to approximately 0.06% of thymic B cells of donor ori-
gin. This gives the impression that thymic B cells are mainly of host origin,
rather than as a result of B cells entering the thymus from the circulation.
This project aimed to further investigate this intrathymic development and the
evidence from the data shown agrees with the hypothesis of intrathymic B cell
development.
Firstly, pro and pre B cells were investigated in the thymus of both NOD and B6
mice and shown to be present. This is similar to the findings of both Hashimoto
et al. [113], who showed presence of pro B cells and a smaller population of
pre B cells in the thymus of BALB/cJ mice, and Akashi et al. [96], who both
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showed presence of pro and pre B cells in the thymus of B6 mice. It would
seem, therefore, that the ability of B cells to develop in the thymus, at least to
the pro B cell stage, is common for both diabetes-prone and diabetes-resistant
strains of mice.
Hashimoto et al. [113] also showed an interesting finding that in BALB/cJ mice,
there was an accumulation of pro B cells in the thymus that were inefficient
at maturing to the pre B cell stage and beyond. Through foetal thymic organ
culture (FTOC), it was hypothesised that the thymic environment renders B
cell progenitors hyporesponsive to lymphopoietic signals, such as IL-7. This
was shown by seeding lobes with B cell progenitors from the bone marrow,
then harvesting the cells at both 2 and 7 days post seeding. Following harvest,
cells were cultured on S17 bone marrow stromal cell lines with B cell permissive
conditions and it was shown that only those harvested at the 2 day time point
were able to produce B cells, whereas the 7 day time point cells were not. Il-7
is important for B cell development [114]. Hashimoto et al. [113] showed that
B cell progenitors from FTOC showed a decreased response to IL-7 compared
to the same B cell progenitors taken directly from the bone marrow. However,
these data were acquired using in vitro approaches therefore it is not known
whether this is applicable to the processes in vivo.
The presence of pro and pre B cells in the NOD thymus suggests that B cells
may be developing there as they are two fundamental stages of normal B cell
development (see Figure 1.1). The findings by Hashimoto et al. [113] could
also suggest a potential mechanism by which B cells are increased in the NOD
thymus compared to the control B6 mouse thymus, in that the NOD thymic
environment may be less effective at dampening B cell progenitor responsed to
lymphopoietic signals, such as IL-7.
Interestingly, it appears that the frequency of the thymic pro B cell population
is dependent on whether or not mature B cells are present. That is, in NOD KO
mice, the frequency of thymic pro B cells was significantly reduced compared
to in both NOD and B6 mouse thymi. Some potential roles of a mature B cell
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include the following:
– A mature B cell may be helping with the recruitment of B cell progenitors
from the bone marrow to the thymus
– A mature B cell may provide a survival factor for B cell progenitors within
the thymus so that they survive to be able to develop
– Mature B cell presence may kick start the process of B cell transcription
factor expression within the thymus, so that the thymus can provide an
environment conducive to B cell development
– A mature B cell may provide a survival factor for newly developed B cells
so that once they have developed, they are able to survive.
A potential mechanism for investigating the role of mature B cells on the thymic
pro B cell population would be to transfer mature B cells from a B cell sufficient
NOD mouse into the NOD KO mouse to see if these donor B cells can have an
effect on the thymic pro B cell population. However, a pilot study of this method
was attempted and showed that the donor B cells did not survive to 11 days
post transfer.
A similar approach to infuse mature B cells into NOD KO mice has also been
attempted by Serreze et al. [85] where mature splenic B cells were transferred
into NOD KO recipient mice. A similar finding was observed in that the B cells
disappeared between 6 and 11 days post transfer. Serreze et al. [85] showed that
this disappearance was due to CTL destruction of the donor B cells, presum-
ably due to the lack of B cell presence during endogenous T cell development,
therefore, the T cells would never have been tolerised to B cells. It is not known
if CTL mediated B cell destruction was also occuring in the transfer utilising
thymic B cells (rather than splenic), or whether it was a different mechanism
causing their disappearance. However, given the fact that these B cells disap-
pear following transfer, it suggests that this approach may not be appropriate
for determining the effect of mature B cells on the thymic pro B cell popula-
tion. For mature B cells to exert their effects on the thymic pro B cells, they may
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need to be present for longer than the period they are detectable in the recipient
NOD KO mice, therefore, an alternative approach must be explored.
Serreze et al. [85] continued investigations by irradiating recipient mice then
transplanting NOD KO bone marrow supplemented with NOD B cells. This
results in endogenous effector immune cells developing in the presence of B
cells and should avoid the T cell destruction of donor B cells. This could, there-
fore, be a way forward to investigate the effect of B cells on the population of
pro B cells in the NOD KO thymus. By adding purified mature B cells, it would
be interesting to see if this was sufficient to increase pro B cell frequency in
the KO thymus. Following this, it would also be of interest to try transplanting
KO bone marrow supplemented with B6 B cells to see if it is a characteristic of
a NOD B cell that can increase thymic pro B cells. However, transfer of B6 B
cells into NOD mice would result in rejection therefore it would be necessary
to use mice such as B6.H-2g7 ([115]) which express NOD MHC and would not
be rejected. This then carries the caveat of the MHC being of NOD origin and
may mean that the differential effects of a NOD B cell and a B6 B cell on the
thymic pro B cell population may be hidden if their action has anything to do
with MHC. Furthermore, it is not known whether the mature B cell needs to
be of splenic or thymic origin, therefore, these experiments could also test this
by separately transferring bone marrow supplemented with B cells from both
tissues.
BcR rearrangement in the thymus
For pro B cells to progress to the pre B cell stage, the IgM heavy chain must be
rearranged. Therefore, it was wondered whether the thymus is able to support
this developmental step. To tackle this question, RAG expression within the
thymic CD19+ cells was assessed in NOD mice. It was seen that there are pop-
ulations of CD19+RAGhigh, CD19+RAGlow and CD19+RAG- cells in the NOD
thymus. The RAGhigh cells are very likely developing there within the thymus
as this very bright signal was equivalent to that seen in actively developing T
cells in the thymus and actively developing B cells in the bone marrow. This
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gives the impression that RAG is being actively transcribed in CD19+ cells in
the thymus, indicating active BcR rearrangement and B cell development. In
addition, if B cells were rearranging their receptors in the bone marrow and
then migrating to the thymus, the GFP expression seen in the thymic B cells
would be lower due to the kinetics of GFP expression. Evidence for this is seen
when screening the blood of GFP+ transgenic mice to see if they are indeed
GFP+. In this case, no GFPhigh cells are seen in the blood of the mice suggest-
ing that GFP expression is decreased following release from the bone marrow.
Therefore, GFPhigh B cell in the thymus is more likely to be due to active de-
velopment there, rather than left over GFP from rearrangement in the bone
marrow (E.A. Green, personal communication).
These RAG expressing CD19+ cells were looked for in NOD-RAG-GFP mice
of 4, 7 and 11 weeks of age and interestingly, the CD19+RAGhigh population
frequency didn’t change, whereas the CD19+RAGlow frequency decreased sig-
nificantly. This gives the impression that as mice age, there are less newly de-
veloped B cells in the thymus, potentially as a result of decreased development.
This decrease suggests that the development of B cells within the thymus may
be restricted to younger mice and that that intrathymic B cell development may
be deactivated at a certain time point in the disease process. However, it may
be that more newly developed B cells are leaving the thymus in older mice
compared to younger ones so that the population of newly developed B cells
within the thymus is decreased.
If the decrease in CD19+RAGlow cells is due to a decrease in development, this
may be due to the fact that within the thymus there are multiple different niches
harbouring different types of cells. For example, the proliferation of DN thymo-
cytes depends on the availability of stromal niches within the thymus and this
is capable, therefore, of regulating the thymus size [116]. It may be that within
the thymus, there is a niche that is more capable of allowing B cell development
than others. Further to this, it may be that this niche is more prevalent in mice of
NOD background compared to non diabetic controls. If this is the case, down-
regulation of B cell development may occur as a result of the thymic B cell niche
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becoming full and competition may prevent the development of more B cells.
Further to this, thymi undergo atrophy with age, therefore, a thymus which is
decreasing in size would have less space available for cells, including B cells, to
reside in, so it may be that with increasing age, B cell development is decreased.
Thymic atrophy is believed to be accelerated in the NOD mouse. As shown by
Ferreira et al. [117], thymic involution and loss of thymic architecture is seen by
9 months of age in the NOD mouse, whereas equivalent thymic degradation in
the B6 mouse is not seen until 15 months of age.
On the other hand, if newly developed B cells are leaving the thymus and trav-
elling elsewhere, it may be that the thymus is acting like the bone marrow,
harbouring B cell development then allowing their release to mature in a dif-
ferent tissue, such as the spleen. In this regard, it would be interesting to know
if thymic egressed B cells contribute to breakdown in peripheral tolerance of T
cells to β cells.
Neither of these suggestions account for the overall picture of an increase in B
cells in the NOD mouse thymus compared to the B6 mouse thymus. It does,
however, suggest that the increased population of thymic B cells may not be
directly linked to the rate of B cell development, but more to proliferation of
developed B cells.
By understanding the kinetics of intrathymic B cell development, and the po-
tential impact of thymic B cells on the normal functioning of the thymus, this
could aid in the design of potential therapeutics. This understanding could el-
lucidate a specific disease time point to target with a therapeutic agent, in order
to have the greatest impact on limiting disease progression.
BLPs are present in the NOD thymus
As mentioned in Section 1.4.1, the commitment of progenitors to the B cell
lineage is thought to occur at the Sca-1lowc-kitlowFlt3+IL-7Rα+Ly6D+ BLP stage
(Figure 1.1, red cell labelled ‘BLP’). Therefore, it was wondered whether these
BLPs would be present in the NOD thymus and, if so, if they are increased in
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the NOD mouse compared to the B6 mouse. When looking for potential TSPs,
cells with the correct markers to allow homing were considered [21], therefore,
it may be that marker expression in the bone marrow is abherrent on B cell
progenitors, resulting in an excess of B cell precursors being able to migrate to
the thymus alongside T cell progenitors. For example, due to their fundamental
role in allowing thymic settling of progenitors, it would be of interest to see how
the levels of Flt3, CCR7 and CCR9 expression compared between bone marrow
BLPs and BLPs found in the thymus [21, 29]. It may be that some express excess
levels of these markers which allow B cell progenitors to migrate to the thymus
along with TSPs.
It was interesting when investigating the presence of BLPs that the frequency of
BLPs in the Sca-1lowc-kitlowFlt3+IL-7Rα+ population in the thymus of the NOD
mouse, was significantly decreased compared to the B6. This was surprising
due to the increased population of B cells seen in the NOD thymus compared
to that of the B6.
However, before any assumptions can be made on this data, it is first necessary
to consider the model of B cell development from BLPs. For example:
– Are BLPs the sole progenitor for B cell development? There is evidence to
suggest that this is a progenitor that is restricted to the B cell lineage [50],
however, it is not clear if this is the only progenitor capable of differentiating
into a B cell.
– Is the B cell developmental pathway the same in the thymus as the bone
marrow? The B cell development pathway in the bone marrow has been in-
vestigated extensively [23], however, the pathway in the thymus is much less
well understood, therefore, whether the bone marrow development pathway
can be applied to the thymus is not known.
In order to help determine the answers to the questions above, it would be
necessary to carry out further experiments. To determine whether B cells can
develop from thymic BLPs, it would be interesting to culture BLPs on thymic
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stromal cell lines, such as OP9-DL1 cell lines (Notch ligand-expressing, bone
marrow derived cell line) which can, to an extent, simulate the thymic environ-
ment [118]. It would, therefore, be useful to see if BLPs are able to develop into
B cells on cell lines such as these. It would also be of use to confirm whether the
BLPs identified in the thymus in this project are able to differentiate into B cells
under the same conditions as those described by Inlay et al. [50] when character-
ising the bone marrow-derived BLP. For this, liquid culture, supplemented with
stem cell factor (SCF), Flt3L and IL-7, was used and differentiation of BLPs into
B cells was seen. By replicating these conditions and culturing thymus-derived
BLPs, it could suggest whether or not they are able to produce B cells in the
way that bone marrow-derived BLPs can.
It is unlikely that B cell development from BLPs is restricted only to the bone
marrow, shown by the presence of BLPs in the B6 thymus. These may be the
origin of the normal, small population of B cells in the B6 thymus. However,
the NOD thymus has a significantly smaller frequency of BLPs in the thymus
compared to the B6. Despite this, NOD mice still have increased thymic B cells
suggesting that there are different mechanisms in the NOD mouse which in-
crease thymic B cells that are not present in the B6 mouse.
Interestingly, when comparing NOD and NOD KO thymic BLPs, there was no
difference observed in the population frequency. This means that if a mature
B cell is having an effect on the pro B cell population, it’s action must be after
the formation of the BLP, and prior to the formation of the pro B cell. For this
reason, it would be of interest to investigate stages between these two cells, to
see whether they are affected by the presence/absence of mature B cells and to
try and pinpoint the time point when mature B cells have their effect.
Do thymic T cells transition to B cells?
To understand another potential mechanism for increased thymic B cells, the
finding of RAG+CD19+CD4+CD8+ cells in the thymus needs to be considered. It
is worth noting that the numbers of mice investigated was relatively small and,
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therefore, requires further repetitions, along with inclusion of B6 control mice
for comparison. However, assuming that this population is a true, distinct cell
population in the thymus of NOD mice, there are a few potential hypotheses
relating to these cells. One in particular is of interest for the increased thymic B
cells seen in the NOD mouse. These cells expressing markers of both T and B
cells suggest that there may be an intrathymic, post-CLP stage when developing
T and B cells express dual T/B cell markers. However, if this is the case, it is
unlikely that this stage is a normal part of B cell development in the bone
marrow due to the lack of RAG+CD19+CD4+CD8+ there.
Thymic progenitors are normally committed to the T cell lineage at the DN
stage, that is, prior to CD4+ and CD8+ expression. It is, therefore, worth consid-
ering whether RAG+CD19+CD4+CD8+ cells represent developing T cells which
are late to commit to the T cell lineage and are retaining some characteristics
of B cells (CD19). On the other hand, they may be cells developing with char-
acteristics of both T and B cells. This may be possible due to the finding of a
small population of cells expressing both a TcR and BcR (IgM+TcRβ+) in the
thymus that may be the mature cell for which RAG+CD19+CD4+CD8+ cells are
the progenitor.
Another possibility which could then contribute to the B cell population in the
thymus, is that these cells are the midpoint of a T cell transitioning to a B cell
(or vice versa, although this would not account for increasing thymic B cells).
This could account for the decreased BLPs in the NOD compared to B6, as
B cells developing from T cells would not develop originally from BLPs and
could, therefore, provide an alternative ‘progenitor’ to a mature B cell.
To investigate the potential for T cell to B cell (or vice versa) transition, it would
be of use to look at the relative levels of B and T cell transcription factors Pax5
and Notch1 in the thymus of NOD mice compared to the thymus of B6 mice.
Maintaining the correct balance of transcription factors is very important for
development of lymphocytes. For example, as mentioned in Section 1.4.2, Pax5
expression is important for repressing T cell lineage commitment through the
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repression of Notch1 [64]. This was shown by expressing Pax5 in all HSCs
and MPPs and it was found that the constitutive expression of Pax5 led to an
increase in B cell development, and a simultaneous decrease in T cell develop-
ment due to Pax5 dependent repression of Notch1. Further to this, deletion of
Notch1 led to a loss of developing T cells and an increase in thymic B cells
[119]. As shown by Feyerabend et al. [119], they found that when Notch1 was
deleted from progenitor T cells, this was associated with an increase in thymic
B cells, some of which arose from the progenitor T cells switching fate from
T to B cell lineage. However, unexpectedly, the majority of these B cells arose
from Notch1 sufficient progenitors and, therefore, became B cells as a result of
a cell-extrinsic factors acting due to the deletion of Notch1 in progenitor T cells.
That said, Notch1 is not the only important transcription factor that needs to
be kept in balance. As mentioned in Section 1.3.2, Gata3 is an important tran-
scription factor for T cell development which requires repression by EBF for
B cell development to occur [120]. Banerjee et al. [120] showed, through the
use of quantitative PCR, that EBF is capable of significantly reducing Gata3
transcription. This was done by transfecting ebf-/- progenitor cells prior to the
pro B cell stage, with EBF and/or Pax5. Following induction of Pax5 expression,
Notch1 transcripts were found to be consistently decreased and EBF expression
reduced Gata3 transcript abundance. This suggests that EBF is also able, to an
extent, to control the T/B cell fate decision and, therefore, any abnormality in
expression levels may affect the populations of B and T cells in the thymus.
In terms of BLPs identified in this project, when Banerjee et al. [120] looked
into the levels of Gata3 transcripts in these cells they found a robust decrease
compared to that seen in all-lymphoid progenitors (ALPs). This coupled with
the lack of T cell lineage cells arising from BLPs suggests that Gata3 may be
downregulated when T cell potential is lost.
Cobaleda et al. [63] have shown that B cells, in the correct conditions, may be
able to de-differentiate back to progenitors, and then differentiate into T cells.
To show this, Pax5 was deleted from mature B cells from Ly5.2+ donor mice and
the B cells were then transferred into recipient Ly5.1+ mice. It was found that
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8 weeks after transfer, some of the donor mature B cells had dedifferentiated
back to the pro B cell stage, shown by their Ly5.2+ pro B cell phenotype. Also,
the recipient mice (that were T cell deficient) showed reconstitution of T cell
development in the thymus 8 weeks following transfer of Pax5 deleted B cells.
These data, combined, show the importance of transcription factor balance. It
may be that in the thymus of NOD mice, an imbalance in transcription factor
expression causes the increased B cell population. Given the information on
transcription factor balance importance above, it would also be beneficial to
compare the relative levels of Notch1 and Pax5, and Gata3 and EBF seen in the
thymus of NOD and B6 control mice. This could indicate any imbalance, unique
to the NOD mouse, which could be accounting for the increased thymic B cell
population seen in the NOD thymus. Unfortunately, due to time constraints,
quantitative PCR studies to assess the transcription factors above could not be
conducted.
In the future, to investigate the potential transitioning of a T cell to a B cell (or
vice versa) in the thymus, RAG+CD19+CD4+CD8+ cells could be isolated and
their final developmental fate determined following incubation with either a
stromal cell line (such as OP9-DL1), or more relevantly, a reaggregated thymic
organ culture (RTOC). In this latter approach, developing thymocytes in ex-
vivo generated foetal thymic organ cultures (FTOCs) would be killed, leaving
the thymic stromal network. This stromal network could then be seeded with
RAG+CD19+CD4+CD8+ cells and their end fate monitored. For example, their
potential progression to IgM+TcRβ+ cells, mature B cells or mature T cells could
be assessed. On the other hand, these further investigations could show that
these RAG+CD19+CD4+CD8+ cells form a distinct population that is unrelated
to other populations seen in the thymus.
4.3. Conclusions and Future Directions
This project aimed to more fully understand potential intrathymic B cell de-
velopment in the NOD mouse model of T1D. These mice show a significant
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increase in thymic B cells when compared to non-diabetes prone mice, such as
the B6 mice used for controls in this project.
There were two main aims for this project. Firstly, the presence of B cell pro-
genitors (at the point of B cell commitment and beyond) within the thymus
was investigated to give an indication as to whether B cell development in the
thymic environment is likely. Secondly, it was wondered whether or not the
thymic environment is able to support the initial IgM heavy chain rearrange-
ment process that is crucial for early B cell development at the pro to pre B cell
transition stage.
Literature to date has suggested that intrathymic B cell development is a likely
process and the data presented in the project supports this hypothesis on a
number of levels.
Due to the literature available on the development of B cells in the bone marrow,
it was hypothesised that the development of B cells within the thymus would
follow a similar pattern. Investigation into this revealed that, in a similar fash-
ion to the bone marrow, the thymus holds populations of pro and pre B cells,
indicative of B cell development there. Further to this, there are CD19+ cells in
the thymus that, via the use of a RAG-GFP reporter mouse, show evidence of
RAG expression. These findings together suggest that the thymic environment
is able to support development of B cells from the pro to pre B cell stage. Inter-
estingly, it appeared that the development of B cells may be age-related, shown
by a decrease in newly developed B cells in the thymus of older NOD mice.
BLP presence in the thymus was also investigated due to evidence that this is
the first progenitor committed to the B cell lineage. Interestingly, while these
were present in the NOD thymus, their frequency was much reduced in the
NOD mouse thymus, in comparison to the B6 control mouse thymus. This find-
ings gives the impression that the increase in thymic B cells seen in the NOD
mouse, compared to the control B6 mouse, is unrelated to the BLP population,
and may indicate an alternative progenitor/mechanism for thymic B cell devel-
opment.
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A hypothesis for a potential alternative developmental pathway arose upon the
finding of RAG+CD19+CD4+CD8+ cells in the NOD thymus. It was postulated
that this population may represent the midpoint of a T cell transitioning to a B
cell and, therefore, present a mechanism by which B cells could be produced
without the BLP progenitor. With this in mind, this could explain why thymic
BLPs are decreased in NOD mice compared to B6 control mice, even though
thymic B cell numbers are increased in the NOD mouse thymus.
These processes occurring in the NOD mouse are summarised in Figure 4.1.
Alongside these potential, abnormal processes, the normal pattern of B cell de-
velopment in the bone marrow, and the pathogenic process occurring in the
islets are shown in the schematic. Of particular interest is the fact that TSPs
(yellow cell) may be retaining B cell potential and differentiating, via the BLP
stage and RAG expression into mature B cells (blue arrows). There is also po-
tential for the existence of cells with characteristics of both B and T cells (green
and grey cell), which may or may not be the result of a redifferentiating T or
B cell (purple arrows). The contribution of thymic B cells to the normal func-
tioning of the thymus is not known, however, it is hypothesised that they may
be contributing to T cell negative selection (black, dashed arrow). It is also not
known how thymic B cells are contributing to the overall disease pathogenesis,
however, it may be that they are moving from the thymus to the islets and
contributing to insulitis.
By understanding the likely intrathymic development of thymic B cells in the
NOD mouse, in the future, it may be possible to manipulate this process to
impact on the disease progression. With this in mind, the field of thymic B cells
may be able to contribute to the discovery and development of new therapeutics
for T1D.
Specific future directions have been outlined within the discussion section of
this project. However, in more general terms, the future direction of this project
should be concerned with aiming to characterise the B cell progenitor respons-
ible for production of thymic B cells. This would indicate whether or not the
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increased thymic B cell numbers in NOD mice, compared to control B6 mice,
is due to an abnormality allowing excess B cell development in the thymus,
or whether it is a lack of regulatory mechanisms relating to their survival. For
example, if the NOD mouse possesses an abnormality which allows seeding of
the thymus with progenitors which have retained B cell potential and preferen-
tially differentiate into B cells, this could account for the increase. On the other
hand, it may be that B cell development in the NOD mouse is normal, but there
is an abnormality in the NOD mouse which allows thymic B cells to survive
and/or proliferate, where they would not be allowed to in control mice.
It would also be of importance to understand the role of the thymic B cell, in
order to know how it functions in T1D. It would be useful to know if it has a
role in driving disease progression, or whether it is more concerned with help-
ing with the purging of autoreactive T cells. It would therefore be an obvious
progression to look into the functioning of thymic B cells and how their ac-
tions have an effect on the T1D pathogenesis. By linking the development and
functioning of thymic B cells, it may be that there is an optimum time point
for intervening in the thymic B cell development process in order to have a
beneficial effect on the disease.
The deepening understanding of the field of thymic B cells has far reaching
consequences, not just in the field of T1D, but in other autoimmune diseases
where increased thymic B cells are also seen. This highlights the relevance of the
research and the importance of its continuation in the future to bring therapies,
as yet undiscovered, one step closer.
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Figure 4.1: Diagrammatical summary of the project findings. B cells develop in the bone mar-
row. T cells develop from thymic settling progenitors believed to be Flt3+CCR7/9+
LMPPs or CLPs which migrate to the thymus. Here they develop into T cells and
pass through negative selection, for which the outcome is either clonal deletion or
release into the periphery. B cells may also be developing in the thymus, either fol-
lowing the same pathway as seen in the bone marrow (bone marrow), or from T
cells developing into B cells (red arrows). There also appears to be evidence of a cell
expressing both T and B cell markers which may arise from a B or T cell that has
been triggered to display both markers (purple arrows), or may be the mid point of
a transitioning T or B cell. Thymic B cells may contribute to insulitis.
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Abbreviations
AIRE Autoimmune Regulator
ALP All lymphoid progenitor
APC Antigen presenting cell
ARRIVE Animal Research: Reporting of In Vivo Experiments
B6 C57BL/6
Bcl11b B cell lymphoma/leukaemia protein 11B
BcR B cell receptor
BLP B cell biased lymphoid progenitor
bp base pair
BSA Bovine serum albumin
CCR7 Chemokine receptor 7
CCR9 Chemokine receptor 9
CD Cluster Differentiation
cDNA Complementary DNA
c-kit Stem cell growth factor receptor
CLP Common lymphoid progenitor
95
cTEC Cortical thymic epithelial cell
CTL Cytotoxic T lymphocyte
CXCL12 C-X-C motif chemokine 12
DAMP Damage-associated molecular pattern
DC Dendritic cell
DN Double negative
DNA Deoxyribonucleic acid
dNTP Deoxynucleotide triphosphates
DP Double positive
DTT Dithiothreitol
E2A Transcription factor 3
EBF Early B cell factor
ETP Early thymic progenitor
Fc Fraction crystallisable
Flt3 Fms-like tyrosine kinase 3
Flt3L Fms-like tyrosine kinase 3 ligand
FOXO1 Forkhead box protein O1
GAD Glutamic acid decarboxylase
Gata3 GATA-binding protein 3
Gfi-1 Growth factor independent 1 transcription repressor
GFP Green fluorescent protein
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HSC Haematopoietic stem cell
IA-2 and 2β Insulinoma antigen 2 and 2β
Ig Immunglobulin
IGRP islet-specific glucose-6-phosphate catalytic subunit-related protein
Ikaros Ikaros family zinc finger protein 1
IL Interleukin
IL-7Rα Interleukin 7 receptor α
KO Knock out
Lin Lineage
LMPP Lymphoid primed multipotent progenitor
Ly6D Lymphocyte antigen 6 complex, locus D
MgCl2 Magnesium chloride
MHC Major histocompatibility complex
MPP Multipotent progenitor
mTEC Medullary thymic epithelial cell
NCBI National Centre for Biotechnology Information
NK cell Natural killer cell
NLR NACHT-leucine rich repeat receptors
NOD Nonobese diabetic
PAMP Pathogen-associated molecular pattern
Pax5 Paired box 5
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PBS Phosphate buffered saline
PCR Polymerase chain reaction
PLN Pancreatic lymph node
PRR Pattern recognition receptor
PU.1 Transcription factor PU.1
RAG Recombination activating genes
rcf Relative centrifugal force
RLR Rig-like receptors
RNA Ribonucleic acid
RSS Recombination signal sequences
Runx RUNT-related transcription factor
Sca-1 Stem cells antigen-1
SCID Severe combined immunodeficiency
SP Single positive
T1D Type 1 diabetes
T2D Type 2 diabetes
TAE Tris acetate-EDTA
TCF-1 T cell factor 1
TcR T cell receptor
TcRβ T cell receptor subunit β
TdT Terminal deoxynucleotidyltransferase
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TLR Toll-like receptor
Treg Regulatory T cell
TSP Thymic settling progenitor
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